

JAMES R. WILLIAMS, County Counsel (S.B. #271253)
JASON M. BUSSEY, Deputy County Counsel (S.B. #227185)
ROBIN M. WALL, Deputy County Counsel (S.B. #235690)
OFFICE OF THE COUNTY COUNSEL
70 West Hedding Street, East Wing, Ninth Floor
San José, California 95110-1770
Telephone: (408) 299-5900
Facsimile: (408) 292-7240

Attorneys for Defendants
JEFFREY V. SMITH and SARA H. CODY

UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA
(San José Division)

RITEESH TANDON, et al.,

Plaintiffs,

v.

GAVIN NEWSOM, et al.,

Defendants.

No. 20CV07108LHK

**DECLARATION OF YVONNE
MALDONADO, MD, IN SUPPORT OF
DEFENDANTS JEFFREY V. SMITH AND
SARA H. CODY'S OPPOSITION TO
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

Date: Dec. 3, 2020
Time: 1:30 p.m.
Crtrm.: 8, 4th Floor
San Jose District Courthouse
280 S. 1st Street
San Jose, California
Judge: Hon. Lucy H. Koh

I, YVONNE MALDONADO, MD, declare as follows:

1. I am currently the Chief of the Division of Pediatric Infectious Diseases, Senior Associate Dean for Faculty Development and Diversity, and Professor of Pediatrics and of Epidemiology and Population Health at the Stanford University School of Medicine. I am also the Medical Director for Infection Prevention and Control and an Attending Physician at the Lucile Packard Children's Hospital in Stanford, California. A true and correct copy of my C.V. is attached hereto as Exhibit A.

2. After receiving my M.D. from the Stanford University School of Medicine, I was a

1 pediatric intern at Stanford and resident at John Hopkins. Following the completion of my
2 residency, I held two fellowships, first at Johns Hopkins Hospital in Pediatric Infections Diseases,
3 and then at the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia.

4 3. My research has focused on epidemiologic aspects of viral vaccine development and
5 prevention of perinatal HIV transmission. I direct a Pediatric Infectious Disease Research Group—
6 the Maldonado Epi Group—at Stanford. The group has been working to identify the molecular
7 epidemiology of factors affecting the immunogenicity of oral polio vaccine (OPV) among children
8 living in developing areas of the world, where OPV immunogenicity is poor. We have identified
9 several factors which affect the poor immunogenicity of OPV and will conduct clinical studies to
10 attempt to improve immunogenicity. We are also working on ways to understand the transmission
11 and circulation of polio vaccine derived viruses, which may cause polio, and how to use this
12 information in global eradication of polio.

13 4. The Maldonado Epi Group recently received a grant from the Bill & Melinda Gates
14 Foundation for a two-and-a-half year study investigating the dynamics of oral poliovirus vaccine
15 (OPV) household and community transmission in three communities in Orizaba, Veracruz, Mexico.
16 The outcome of this project will inform public policy decision-making regarding OPV cessation and
17 the polio end-game.

18 5. In a previous 15-year project, our group worked to define the ontogeny of the
19 immune response to measles vaccine among young infants. The purpose was to identify specific
20 humoral and cell-mediated immune responses to measles vaccine which affect vaccine
21 immunogenicity and induce the immunosuppressive effects associated with measles vaccination.

22 6. We are also currently conducting a number of COVID-19 studies. In a large-scale
23 research collaboration between Stanford University, the University of California, San Francisco
24 (UCSF), and the Chan Zuckerberg Biohub, we are conducting a nine-month study to better
25 understand the prevalence of COVID-19 across the San Francisco Bay Area. In that study, which
26 George W. Rutherford, MD (UCSF) and I are leading as principal investigators, we will recruit and
27 test a representative sample of roughly 4,000 Bay Area residents who have previously tested
28 negative for COVID-19. We will then re-test the participants monthly through both polymerase

1 chain reaction (PCR) diagnostic testing and serological (“antibody”) testing to investigate
2 transmission dynamics and disease prevalence.

3 7. My research group is also conducting a study comparing nasal swab self-collection
4 versus collection by health care workers for COVID-19 testing to validate a COVID-19 home swab
5 test kit for an upcoming antiviral clinical trial. Should self-collected nasal swabs prove as effective
6 as those collected by health care workers, patients may be able to safely and effectively collect
7 specimens outside of health care settings.

8 8. Finally, the group is conducting a study of the shedding and household transmission
9 of COVID-19. The study will combine genomic and epidemiologic data to address questions about
10 the transmission and evolutionary dynamics of COVID-19. We plan to use whole-genome
11 sequencing to understand how COVID-19 mutates during the early stages of infection, as well as
12 generate a bio-repository of specimens and associated clinical and epidemiologic data for use in
13 understanding the transmission of COVID-19.

14 9. I have published 178 peer-reviewed articles and a large number of other publications,
15 including non peer-reviewed journal articles and conference papers, and served as co-editor of two
16 infectious diseases textbooks.

17 10. I teach, mentor, and advise ungraduated and graduate students at Stanford, and I am
18 currently teaching a course on the epidemiology of infectious diseases.

19 11. The County defendants in this case contacted me about providing an expert opinion
20 regarding the declarations of Dr. Jay Bhattacharya and Dr. Rajiv Bhatia. I agreed to provide a
21 declaration setting forth my professional opinions on the issues raised in those declarations. In
22 reaching those opinions, I have relied on my knowledge, experience, and the kinds of data regularly
23 relied on by experts in my field. If called as a witness, I could and would testify competently to the
24 matters set forth herein. I am working pro bono and not being compensated for my time.

25 12. I have read the declarations of Dr. Jay Bhattacharya and Dr. Rajiv Bhatia submitted
26 by the plaintiffs in this lawsuit. My opinions regarding those declarations are based on the available
27 science regarding COVID-19 and my training and experience in epidemiology and as an infectious
28 disease researcher and clinician.

The State and County Public Health Orders

13. The public health measures taken by the State of California and the County of Santa Clara are supported by credible science and represent the current international consensus among epidemiologists and infectious disease specialists regarding the appropriate response to the COVID-19 pandemic. The State and County public health orders require face coverings and impose social distancing requirements and limit gathering sizes based in part on measurements of the community prevalence of the virus—current case counts and positivity rates. Using face coverings, social distancing, and limiting the size of gatherings, particularly indoors, are all consensus measures to reduce community transmission of the SARS-CoV-2 virus that causes COVID-19. These measures are effective because SARS-CoV-2 is highly contagious and spread mainly through infectious respiratory droplets and aerosols.

14. The use of face masks have been shown to substantially reduce the spread of COVID-19.¹ The U.S. Centers for Disease Control and Prevention (CDC) recently concluded that the benefits of masking derive from the combination of source control—reducing the emission of virus-laden droplets—and personal protection for the mask wearer—reducing the inhalation of these droplets by the wearer; and that the relationship between source control and personal protection is likely complementary and possibly synergistic, so that the benefit to the individual increases with increasing community mask use.² Indeed, masking and other measures are critical to avoid a return to the shelter-in-place orders necessary at the outset of the pandemic. As the CDC concluded: “Adopting universal masking policies can help avert future lockdowns, especially if combined with other non-pharmaceutical interventions such as social distancing, hand hygiene, and adequate ventilation.”³

¹ Lyu W., et al., *Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US*, Health Affairs, 39, No. 8 (2020): 1-7, doi: 10.1377/hlthaff.2020.00818.

² CDC, *Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2*, Nov. 10, 2020, available at <https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html>.

³ *Id.*

1 15. The use of social distancing has also been shown to reduce the spread of COVID-19
 2 and halt the exponential growth in case counts, *i.e.*, flattening the curve. In the absence of a vaccine
 3 or effective antiviral treatment, social distancing may be one of the most effective means of slowing
 4 community transmission.⁴ Social distancing measures reduce the number of close contacts during
 5 which transmission may occur. For example, one study estimated that without the shelter-in-place
 6 orders in place at the outset of the pandemic, the viral spread would have been ten times greater.⁵
 7 On the other hand, premature easing of social distancing today could result in increased
 8 transmission.⁶

9 16. Similarly, limiting the size of indoor and outdoor gatherings has been shown to
 10 reduce the spread of the disease.⁷ Crowded indoor spaces in particular are settings that significantly
 11 increase the risk of community spread of SARS-CoV-2. Closing restaurants, bars and
 12 entertainment-related businesses has been shown to substantially slow the spread of COVID-19.⁸

13 17. Dr. Bhatia’s opinion that there is “no scientific or ethical justification” for the State
 14 and County public health orders is wrong. Those orders have saved thousands of Californians from
 15 serious illness, hospitalization, and death. By flattening the curve and avoiding exponential growth
 16 in infections and illness, those orders bought time to expand surveillance and testing; to develop
 17 treatment strategies that have improved clinical outcomes; and to make progress toward an effective
 18 vaccine.

19 **Herd Immunity Is Not A Safe Public Health Strategy**

20 18. On September 9 2020, I joined a letter with 106 of my colleagues at Stanford,
 21 representing infectious diseases physicians and researchers, microbiologists and immunologists,
 22
 23

24 ⁴ Alagoz, O., et al., *Effect of Timing of and Adherence to Social Distancing Measures on COVID-19*
Burden in the United States, Ann. Intern. Med. 2021. doi:10.7326/M20-4096.

25 ⁵ Courtemanche C, et al.. *Strong social distancing measures in the United States reduced the*
 26 *COVID-19 growth rate*, Health Affairs (Millwood), 2020;39(7), doi:10.1377/hlthaff.2020.00608.

27 ⁶ Alagoz 2020, *supra*.

28 ⁷ Chang, Serina, et al., *Mobility network models of COVID-19 explain inequities and inform*
reopening, Nature, Nov. 10, 2020, <https://doi.org/10.1038/s41586-020-2923-3>.

⁸ Courtemanche 2020, *supra*.

1 epidemiologists and health policy leaders to promote science-based responses to COVID-19 that
 2 advance human health and prevent suffering. My colleagues and I were unanimous in concluding
 3 that the herd immunity approach championed by individuals like Drs. Bhattacharya and Bhatia—
 4 encouraging herd immunity through unchecked community transmission—is not a safe public health
 5 strategy. As the letter attests, this is the overwhelming consensus of the relevant experts at Stanford.

6 19. Relaxing or eliminating the public health measures designed to reduce community
 7 transmission will lead to a significant—even exponential⁹—increase in preventable cases, suffering
 8 and deaths, especially among vulnerable populations, such as older individuals, younger individuals
 9 with pre-existing conditions, and essential workers. Research has shown that social distancing
 10 measures reduce transmission and that premature easing of social distancing measures or low rates
 11 of community adherence to them could result in a rapid return to exponential growth of COVID-19
 12 cases in communities.¹⁰

13 20. Reducing or eliminating community transmission is critical to protecting essential
 14 workers and vulnerable populations. While we should take additional steps to protect those that are
 15 most vulnerable to COVID-19—and I understand that County has done exactly that¹¹—those
 16 focused measures are not by themselves a sufficient response to the pandemic. Contrary to the
 17 arguments of Drs. Bhattacharya and Bhatia, it is not possible to effectively protect essential workers
 18 and vulnerable populations without also controlling community transmission. For example, social
 19 distancing is not an option for the millions of healthcare workers still providing important and
 20 necessary healthcare—they cannot simply isolate themselves. A 2018 survey estimated that doctors
 21

22 ⁹ Courtemanche 2020, *supra*.

23 ¹⁰ Oguzhan A., et al., *Effect of Timing of and Adherence to Social Distancing Measures on COVID-19 Burden in the United States, A Simulation Modeling Approach*, Ann Intern Med. 2021.
 24 doi:10.7326/M20-4096.

25 ¹¹ County of Santa Clara Public Health Department, *Licensed Skilled Nursing Facilities and Other Long-Term Care Facilities; Assisted Living Facilities and Independent Living Facilities; Residential Care and Crisis Residential Facilities in Santa Clara County*, available at
 26 https://www.sccgov.org/sites/phd-p/Diseases/novel-coronavirus/Documents/Long-Term_Care_Facilities_Memo_213RR_Sample_Final_4.5.20.pdf; *Updated COVID-19 Requirements, Guidance, and Strategies for LTCFs in Santa Clara County*, <https://www.sccgov.org/sites/phd-p/Diseases/novel-coronavirus/Documents/updated-covid-19-requirements-for-LTCFs-090420.pdf>.
 27
 28

1 see an average of 20 patients per day, in addition to the members of their health care team.¹² The
 2 probability of transmission from a community member to a health care worker rises with the
 3 prevalence of infection in the community.¹³ While the use of personal protective equipment
 4 (PPE)—where available—can substantially mitigate this risk,¹⁴ it cannot eliminate it; and reducing
 5 community transmission remains an important measure to protect health care workers.

6 21. Protecting vulnerable populations presents similar issues. Not all vulnerable
 7 Americans can self-isolate. For example, Americans ages 65-74 are five times more likely to be
 8 hospitalized with COVID-19 and 90 times more likely to die than Americans aged 18-29; and the
 9 risks of hospitalization and death continue to rise with age.¹⁵ However, an estimated 5.77% of
 10 California households—more than 750,000—are multigenerational, meaning that they include two
 11 or more adult generations or grandparents and grandchildren younger than 25.¹⁶ According to a Pew
 12 Research study, in 2016, 64 million people, or 20% of the U.S. population lived in a
 13 multigenerational home.¹⁷ Older Americans living in these homes may not be able to self-isolate,
 14 particularly when they are the principal caregivers for their grandchildren.

15 ///

16
 17
 18 ¹² 2018 Survey of America's Physicians Practice Patterns and Perceptions, The Physicians
 19 Foundation, available at
 20 <https://physiciansfoundation.org/wpcontent/uploads/2018/09/physicianssurvey-results-final-2018.pdf>
 21 (accessed Apr. 3, 2020).

22 ¹³ Graham, L., et al., *Asymptomatic SARS-CoV-2 Transmission from Community Contacts in*
 23 *Healthcare Workers*, Annals of Surgery (preprint), doi: 10.1097/SLA.0000000000003968.

24 ¹⁴ Gralton, J., et al., *Protecting healthcare workers from pandemic influenza: N95 or surgical*
 25 *masks?*, Critical care medicine. 2010;38(2):657-667; Offeddu, V., et al., *Effectiveness of masks and*
 26 *respirators against respiratory infections in healthcare workers: a systematic review and meta-*
 27 *analysis*. Clinical Infectious Diseases. 2017;65(11):1934-1942.

28 ¹⁵ CDC, *COVID-19 Hospitalization and Death by Age*, available at
<https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html>.

¹⁶ Hoff M., *Social distancing may be harder for families who live with elderly relatives. Here are the*
15 states with the largest share of multigenerational households, Business Insider, Apr. 25, 2020,
 available at <https://www.businessinsider.com/the-states-with-the-most-multigenerational-households-2020-4>.

¹⁷ Cohn D, et al., *A record 64 million Americans live in multigenerational households*, Apr. 5, 2018,
 available at <https://www.pewresearch.org/fact-tank/2018/04/05/a-record-64-million-americans-live-in-multigenerational-households/>.

Hospitalization Rates Are Not A Substitute For The Use Of PCR Data

22. Dr. Bhattacharya's criticism of the use of PCR data in public health policy and decision making is misplaced.

23. Reverse transcription polymerase chain reaction (RT-PCR or PCR) tests are the standard for many disease diagnostics, including COVID-19. PCR tests are a rapid and accurate means of diagnosing the disease among suspected cases. And confirmed COVID-19 case counts and positivity rates are a vital measure of disease prevalence. This data is vital to limit the spread of the virus.

24. Of course PCR tests are not the sole surveillance method that epidemiologists use. Seroprevalence studies—tests that identify whether individuals are carrying antibodies for SARS-COV-2—are another helpful metric. One of my research groups's ongoing studies of COVID-19 will be using both PCR and seroprevalence testing to study transmission dynamics and disease prevalence.

25. Hospitalization rates are another measure used by epidemiologists to evaluate disease severity and burden. However, Dr. Bhatia is incorrect that instead of PCR case counts and positivity rates, we should be "[u]tilizing laboratory-confirmed hospital cases to calibrate a public health response" (Para. 48). Again, this data is complementary to PCR and seroprevalence data, and not a substitute for either. Hospitalization rates and capacity measures are lagging indicators for COVID-19, as hospitalization follows infection—studies estimate 9.5-12 days from onset to ICU admission¹⁸—and capacity measures are not ideal because once the number of new infections increases to a level at which the health care system becomes burdened by the resulting hospitalizations, reimplementation of mandated social distancing is less effective at mitigation than earlier implementation.¹⁹ For example, in a study of the pandemic response in Wuhan and Guangzhou, China, lockdowns did not lead to an immediate reduction in hospital utilization. The

¹⁸ CDC, *Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)*, available at <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html> (visited No. 13, 2020).

¹⁹ Alagoz 2020, *supra*.

1 study attributed the delay in reducing hospital utilization to the potentially long time from infection
 2 to severe and critical condition, as many patients with COVID-19 who eventually require ICU care
 3 present initially with only mild symptoms, and an even longer time to discharge or death, resulting in
 4 the accumulation of hospitalized cases long after downturns in community spread.²⁰

5 26. Relying on hospitalization data while allowing unrestricted community transmission
 6 of the virus among younger populations is an extremely risky approach. Because hospitalization and
 7 capacity measures are lagging indicators, the expected rapid or exponential growth in community
 8 transmission that would accompany a “herd immunity approach” could result in overwhelming
 9 health care systems. This was the lesson of Wuhan, China, Turin, Italy, and New York City.²¹ It is
 10 not a lesson we should ignore in California.

11 I declare under penalty of perjury under the laws of the United States of America that the
 12 foregoing is true and correct. Executed at Stanford, California on November 18, 2020.

13
 14 /S/ Yvonne Maldonado

15 YVONNE MALDONADO, MD
 16
 17
 18
 19
 20
 21
 22
 23
 24

2309536

25 ²⁰ Li, R., *Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients*
 26 *With COVID-19 Based on Comparisons With Wuhan and Guangzhou, China*, May 6, 2020, JAMA
 Netw Open. 2020;3(5):e208297. doi:10.1001/jamanetworkopen.2020.8297.

27 ²¹ Van Beusekom, M., *Study: Wuhan-like COVID-19 scenario could crush US hospitals*, CIDRAP
 28 News, May 6, 2020, available at <https://www.cidrap.umn.edu/news-perspective/2020/05/study-wuhan-covid-19-scenario-could-crush-us-hospitals>.

EXHIBIT A

I. Biographical Information

YVONNE (BONNIE) AIDA MALDONADO

Business Address: Department of Pediatrics
Division of Infectious Diseases
Stanford University School of Medicine
300 Pasteur Drive
Stanford, CA 94305-5119

(650) 723-5682
Email: bonniem@stanford.edu

A. IDENTIFYING DATA

1. Place of birth Los Angeles, California
2. Citizenship United States

B. ACADEMIC HISTORY

1. Education
September 1973 - June 1977 University of California, Los Angeles
B.A., Bacteriology, 1977
September 1977 - June 1981 Stanford University School of Medicine
M.D., 1981

2. Pre-doctoral scholarships and academic honors

1973 Bank of America Scholarship
1973 - 1977 Western United States and Canada Regional AFL-CIO
Undergraduate Scholarship
1977 - 1978 National Medical Fellowship Scholarship
1977 - 1980 Mabel Wilson Richards Medical Student Scholarship
1979 - 1980 Ruth G. White P.E.O. Medical Scholarship

3. Post-doctoral and residency training

July 1981 - June 1982 Intern, Department of Pediatrics Stanford University School of
Medicine Stanford, CA
July 1982 - June 1984 Resident, Department of Pediatrics Johns Hopkins University
Baltimore, MD
July 1984 - June 1986 Fellow, Infectious Diseases Department of Pediatrics
Johns Hopkins University

4. Other study and research opportunities

July 1986 - June 1988 Epidemic Intelligence Service Officer Centers for Disease Control
Assigned to State of California, Department of Health Services,
Infectious Disease Branch

Grant Support

Past

1988 - 1989	Katherine McCormick Research Fellowship Stanford University School of Medicine Principal Investigator: Yvonne A. Maldonado, MD
1988 - 1993	University of California, San Francisco 1236SC-03-1-4 subcontract National Institutes of Health Northern California Pediatric AIDS Clinical Trials Group Principal Investigator: Yvonne A. Maldonado, MD
1989 - 1998	Centers for Disease Control Cooperative Agreement U64/CCU901179 University-based Active Surveillance for Pediatric AIDS in Northern California Principal Investigator: Yvonne A. Maldonado, MD
1990	Biomedical Research Support Grant Stanford University School of Medicine Epidemiology of Poliovirus Infection Among Rural Mexican Children and Characterization of the Humoral Immune Response to Oral Trivalent Poliovirus Vaccine (OPV) Principal Investigator: Yvonne A. Maldonado, MD
1991	Office of Technology Licensing Research Incentive Fund Stanford University School of Medicine Duration of Maternally-Acquired Measles Antibody: Comparison of Infants of Mothers with Wild Type versus Vaccine-Induced Immunity Principal Investigator: Yvonne A. Maldonado, MD
1992 - 1997	National Institutes of Health RO1-AI31475 Enterovirus Prevalence and Effect on OPV Immunogenicity Principal Investigator: Yvonne A. Maldonado, MD
1995 - 1998	Glaxo, Inc. A Randomized Comparative Study of Combined Zidovudine (ZDV) - Lamivudine (3TC[TM]) vs. the Better of DDI Monotherapy vs. Zidovudine Plus DDI in Symptomatic HIV-1- Infected Children Principal Investigator: Yvonne A. Maldonado, MD
1996 - 1998	Child Health Research Fund Department of Pediatrics Stanford University School of Medicine Immunogenicity of Trivalent Oral Poliovirus Vaccine (OPV) and Correlates of Neuroreversion of Sabin type 3 Vaccine Virus Principal Investigator: Yvonne A. Maldonado, MD

1997 - 1998	Pasteur-Merieux Connaught, Inc. Host and Viral Factors Associated with Neuroreversion of Sabin Type 3 Poliovaccine Virus Principal Investigator: Yvonne A. Maldonado, MD
1996 - 1999	Amgen, Inc. A Multicenter, Double-blind Randomized, Placebo- controlled Phase II Safety and Efficacy Study of Filgrastim (r-metHuG-CSF) in the Treatment of Late- onset Neonatal Sepsis Co-Principal Investigator: Yvonne A. Maldonado, MD
1998 -1999	Family Health International/National Institutes of Health Clinical Trials of Vaccine and Non-Vaccine Interventions for HIV Prevention in Developing Countries through the HIVNET Co- Investigator: Yvonne A. Maldonado, MD
1989 -2000	California Department of Health Services Contract 93-17976 University-based Active Surveillance for Pediatric AIDS in Northern California Principal Investigator: Yvonne A. Maldonado, MD
1995 - 2000	National Institutes of Health - AI 94029 Vertical Transmission of HIV in Zimbabwe Principal Investigator: David Katzenstein, MD Co-Principal Investigator: Yvonne A. Maldonado, MD
2000	Pharmacia & Upjohn Linezolid vs. Cefadroxil in the Treatment of Skin and Skin Structure Infections in Children Principal Investigator: Yvonne A. Maldonado, MD
1999 - 2000	Family Health International/National Institutes of Health Clinical Trials of Vaccine and Non-Vaccine Interventions for HIV Prevention in Developing Countries through the HIVNET Principal Investigator: Yvonne A. Maldonado, MD
1998 - 2001	Child Health Research Fund Stanford University School of Medicine Neutrophil CD11b expression, a novel method of detecting serious bacterial infections in outpatient febrile infants and children 30 days to 36 months of age Principal Investigator: Yvonne A. Maldonado, MD
1997 - 2001	National Institutes of Health Ontogeny of Perinatal Host Defenses Principal Investigator: David Lewis, MD Co-Investigator: Yvonne A. Maldonado, MD
2001	Elizabeth Glaser Pediatric AIDS Foundation Short-term Award (First award) Principal Investigator: Yvonne A. Maldonado, MD

2001	Elizabeth Glaser Pediatric AIDS Foundation Short-term Award (Second award) Principal Investigator: Yvonne A. Maldonado, MD
2000 -2004	California Department of Health Services Contract 93-17976 University-based Active Surveillance for Pediatric AIDS in Northern California Principal Investigator: Yvonne A. Maldonado, MD
2001 - 2004	National Institutes of Health R34 Statistical Center for Rotavirus Vaccine in India Principal Investigator: Yvonne A. Maldonado, MD
2002-2004	Elizabeth Glaser Pediatric AIDS Foundation Call to Action Award Principal Investigator: Yvonne A. Maldonado, MD
2003-2007	National Institutes of Health R01 Indo-US Collaboration to Develop Rotavirus Vaccines Co-Principal Investigator: Yvonne A. Maldonado, MD
2006-2008	Howard G. Buffett Foundation Eliminating Polio through Safe Vaccination Principal Investigator: Yvonne A. Maldonado, MD
2000 - 2008	National Institutes of Health U01 AI047995 Clinical Trials of Vaccine and Non-Vaccine Interventions for HIV Prevention in Developing Countries through the HIV Prevention Trials Network Co-Principal Investigator: Yvonne A. Maldonado, MD Perinatal Principal Investigator: Yvonne A. Maldonado, MD
2007-2010	National Institutes of Health International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Leadership Group Member, Network Executive Committee
1999 -2010	California Department of Health Services Enhanced Surveillance for Perinatal HIV Infection Principal Investigator: Yvonne A. Maldonado, MD
1994 - 2011	National Institutes of Health U01 AI37127 Ontogeny of Measles Immunity in Infants Principal Investigator: Ann M. Arvin, MD Co-Principal Investigator: Yvonne A. Maldonado, MD
1999 - 2011	California Department of Health Services Enhanced Prevention of Perinatal Transmission of HIV – Rapid Testing in Labor and Delivery Principal Investigator: Yvonne A. Maldonado, MD

2005-2013	California Department of Health Services 05-46026 HIV Medical Monitoring Project Principal Investigator: Yvonne A. Maldonado, MD
2007-2013	National Institutes of Health R01AI068577 Vaccination Strategies after Elimination of Poliomyelitis Principal Investigator: Yvonne A. Maldonado, MD
2007-2012	National Institutes of Health subcontract from UCSF HPTN 046: “A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission during Breastfeeding” Protocol Co-chair and Zimbabwe PI: Yvonne A. Maldonado, MD
2008-2013	National Institutes of Health T32 Training Grant in Pediatric Infectious Diseases: Viral Infections in Children Program Director: Yvonne A. Maldonado, MD
2008-2013	National Institutes of Health T32 Training Grant in Epidemiology Program Director: Julie Parsonnet Program Co-Director: Yvonne A. Maldonado, MD
2009-2011	Centers for Disease Control and Prevention ARRA Vaccine Safety and Safety Communication Curriculum for Medical Residents Stanford PI: Yvonne A. Maldonado, MD
2010-2012	World Health Organization Post Eradication Polio Vaccination Strategies: Effect of routine IPV immunization on OPV, VAPP, and VDPV shedding in Mexico after NIDS PI: Yvonne A. Maldonado, MD
2010-2013	National Institutes of Health International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Leadership Group Member, Scientific Oversight Committee
2013-2014	Bill and Melinda Gates Foundation Correlation of OPV VP1 Genome Mutations with Development of Pre-VDPV and VDPV in Young Infants Principal Investigator: Yvonne A. Maldonado, MD
2010-2015	National Institutes of Health Novel Education Clinical Trainees and Researchers (NECTAR) PI: Barry; Investigator: Yvonne A. Maldonado, MD

2011-2015	National Institutes of Health/Biomedical Research and Training Institute of Zimbabwe ICOHRTA-African Program for Training in HIV/TB Co-investigator: Yvonne A. Maldonado, MD
2011-2017	National Institutes of Health/University of California, San Francisco UZ/UCSF-CTU Co-investigator: Yvonne A. Maldonado, MD
2012-2017	National Institutes of Health/ University of California R01 AI100748 Lamivudine and its Impact on Perinatal HBV Transmission in HIV/ HBV Coinfection Co- investigator: Yvonne A. Maldonado, MD
2013-2018	National Institutes of Health R01 AI06858106 Public HIV Drug Resistance Database Co-investigator: Yvonne A. Maldonado, MD
2014-2018	Bill and Melinda Gates Foundation OPV Transmissibility in Communities after Cessation of Routine OPV Immunization Principal Investigator: Yvonne A. Maldonado, MD
2015-2018	American Refugee Committee (USAID primary funder) Asili Project Evaluation in the Democratic Republic of Congo Stanford Principal Investigator: Yvonne A. Maldonado, MD
<u>Present</u>	
2014-2024	Bill & Melinda Gates Foundation Stanford Human Systems Immunology Center Investigator: Yvonne A. Maldonado, MD
2016-2021	National Institutes of Health U54MD010724 Stanford Precision Health for Ethnic and Racial Equity (SPHERE) Transdisciplinary Collaborative Center Co-Principal Investigator (Multi-PI): Yvonne A. Maldonado, MD
2016-2021	National Institutes of Health T32 AI052073 Training Grant in Epidemiology Program Director: Julie Parsonnet Program Co-Director: Yvonne A. Maldonado, MD
2017-2020	Thrasher Foundation Prevention of Congenital Toxoplasmosis: Feasibility of Prenatal Screening Using Point-of-Care Tests Principal Investigator: Yvonne A. Maldonado, MD

2020-2022	National Institutes of Health R21AI 148810-01 A genomic tool for identifying pathogenic circulating vaccine-derived Polioviruses Principal Investigator: Yvonne A. Maldonado, MD
2020	Anonymous Donor Natural History of Shedding and Household Transmission of COVID-19:SARS-CoV2 Principal Investigator: Yvonne A. Maldonado, MD
2020	Chan Zuckerberg Initiative California Pandemic Consortium: Track COVID and CHART Studies, an Epidemiologic Approach to tracking the COVID pandemic in the 6 country San Francisco Bay Area Stanford Principal Investigator: Yvonne A. Maldonado, MD
2020	Anonymous Donor and FujiPharma, LLC A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects with Mild or Asymptomatic COVID-19 Principal Investigator: Yvonne A. Maldonado, MD

C. EMPLOYMENT

August - September 1988: Acting Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California

September 1988 - August 1997: Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California

September 1997 – August 2007: Associate Professor, Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California

September 2000 – September 2007: Associate Professor, by courtesy, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California

November 2006 –September 2008: Acting Chief, Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California

October 2007- present: Professor, Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California

October 2007- September 2010: Professor, by courtesy, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California

September 2008– present: Chief, Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California

October 2010- present: Professor, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California

May 2014-present: Senior Associate Dean for Faculty Development and Diversity, Stanford University School of Medicine, Stanford, California

D. PUBLIC AND PROFESSIONAL SERVICE

Committees

1983	Consultant, National Geographic Society
1985	Consultant, Pan-American Health Organization Program of Management of Acute Respiratory Infections in Developing Countries
1988	Technical Advisor for AIDS Epidemiology in Central America, Pan-American Health Organization
1989-1990	Member, Epidemiology/Prevention Program Committee, 6 th International Conference on AIDS
1989-	Faculty advisor to Pediatric Residents, Stanford University
1990-1991	Member, Epidemiology/Prevention Program Committee, 7 th International Conference on AIDS
1988-	Director, California Children's Services Infectious Disease and Immunology Center, Stanford University Medical Center
1988-	Member, Stanford University School of Medicine Admissions Panel
1989-	Member, California Children's Services HIV/AIDS Technical Advisory Committee
1990	Member California AIDS Leadership Committee, Perinatal and Pediatric Testing Subcommittee
1991-1993	Executive Steering Committee, Stanford Center for Chicano Research
1991-1994	Member, Anti-Infective Drugs Advisory Committee of the Food and Drug Administration
1992-1995	Member, Council on Diversity, Stanford University School of Medicine
1993-1996	Member, National Pediatrics Review and Educational Program (PREP) American Academy of Pediatrics
1994	Ad hoc study section member, Epidemiology and Disease Control Study Section 2, National Institutes of Health (declined full membership to study section)
1995	Member, Ad hoc committee on Pediatric Sedation Standards, Food and Drug Administration
1996-2001	Executive Steering Committee, Stanford Center for Chicano Research
1997	Session Chair, Infectious Diseases Session, Meeting of the Western Society for Pediatric Research, Carmel, CA, February 1997
1997-2001	Chicano Studies Curriculum Committee, Center for Comparative Studies on Race and Ethnicity, Stanford University
1997	Institute of Medicine, Position Paper on Pediatric HIV and other Pediatric Infections for the Committee on the Health and Adjustment of Immigrant Children
1997	National Institute of Allergy and Infectious Diseases, Focus Group on Improving Academic Research Opportunities for Minority Biomedical Physicians and Scientists
1997	National Institute of Allergy and Infectious Diseases, Review Panel Member, Demerging Diseases Supplements: Virology
1998	Member, National vaccine Advisory Committee United States Public Health Service
1998	Ad hoc member, Vaccine Advisory Committee, Food and drug Administration
1998-2001	Member, University of California University-wide Task Force on AIDS
1998-2001	Member, University of California University-wide Task Force on AIDS, subcommittee on the AIDS Clinical Research Centers (ACRC)

1998	National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases Focus group on Programs in International Research
1999	Co-Chair, Infectious Diseases Committee, Northern California Chapter, American Academy of Pediatrics
1999-	Perinatal Principal Investigator, Zimbabwe HPTN 023 and 046 studies
2000-2001	Chair, University of California University-wide Task Force on AIDS
2000	Member, Polio Laboratory Containment Workgroup, National Vaccine Advisory Committee
2000	Member, Perinatal Working Group, HIV Prevention Trials Network, National Institutes of Health
2001-2005	Member, Appointments and Promotions Committee, Department of Pediatrics, Stanford University School of Medicine
2001	Member, Health Services Research Interdepartmental Program Review Committee, Stanford University School of Medicine
2001-2005	Member, Committee on Faculty and Staff Benefits, Stanford University
2001-2002	Member, Core Advisory Group for the California Border/Central Valley AIDS Initiative
2001-2002	Member, School of Medicine Committee on Women and Medicine in Science
2001-2002	Member, School of Medicine Committee on Faculty Diversity
2001-2002	Member, Stanford University Committee on Faculty Diversity
2001	Member, Department of Pediatrics Nominations Committee
2002-2005	Member, Microbiology and Infectious Disease Research Committee, NIAID, National Institutes of Health
2002	Member, Stanford University School of Medicine Curriculum Scholarly Tracks Committee
2002-2006	Member, Stanford University Biosafety Panel
2003-2006	Member, Space and Staffing Committee, Lucile Salter Packard Children's Hospital at Stanford
2003-2006	Member, FPO ACC Quality Assurance Committee
2003-2006	Member, Stanford University School of Medicine Faculty Senate
2004-2008	Member, Pharmacy and Therapeutics Committee, Lucile Salter Packard Children's Hospital at Stanford
2005-2010	Member, Network Executive Committee, NIH-funded International Maternal, Pediatric, and Adolescent AIDS Clinical Trials Group - IMPAACT) Planning Committee
2005-	Member, Steering Committee, Children's Health Research Program, Department of Pediatrics Stanford University School of Medicine
2006-	Medical Director, Infection Control Program, Lucile Salter Packard Children's Hospital at Stanford
2006	Course director, Current Trends in Pediatric Vaccination: Strategies to Achieve Compliance
2007	Special Emphasis Panel, NIAID Clinical Training Planning (R34) Grants and Implementation (U01) Cooperative Agreements
2008-2011	Member, Appointments and Promotions Committee, Stanford University School of Medicine
2008-2012	Member, Clinical Research and Field Studies of Infectious Diseases Study Section, CSR, NIH
2008-	Stanford University School of Medicine Awards Committee
2010-2011	Chair, Appointments and Promotions Committee, Stanford University School of Medicine
2010-2016	Member, Committee of Infectious Diseases, American Academy of Pediatric
2010-2013	Member, Scientific Oversight Committee, NIH-funded International Maternal, Pediatrics, and Adolescent AIDS Clinical Trial Group (IMPAACT) Planning Committee
2011-	Member, Faculty of 1000, Pediatric Infectious Diseases
2012-2017	Member, March of Dimes Grant Review Committee
2012-	Member, Global Vaccine Advocacy Committee, American Academy of Pediatrics
2012-2016	Member, National Vaccine Advisory Committee, Department of Health and Human Services
2014-	Member, External Advisory Board, Instituto Nacional de Salud Publica, Cuernavaca, Mexico
2014-2018	Vice Chair, Committee on Infectious Diseases, American Academy of Pediatrics

2016-2019 Member, Board of Directors, Pediatric Infectious Diseases Society of American
 2016-2019 Member, Task Force on Diversity and Inclusion, American Academy of Pediatrics
 2016- Member, Board of Scientific counselors, Office of Infectious Disease, Centers for Disease Control and Prevention
 2017- Member, Transition Independent Monitoring Board for the Global Polio Eradication Initiative
 2017 Member, Poliovirus Containment Advisory Group, World Health Organization
 2018-2022 Chair, Committee on Infectious Diseases, American Academy of Pediatrics
 2019-2022 Member, Committee on Diversity and Inclusion, American Pediatric Society
 2019-2020 Member, California Precision Medicine Advisory Committee
 2020 Member, California COVID-19 Academic Advisory Committee
 2020 Member, California Scientific Safety Review Workgroup

Journal Reviewer

American Journal of Epidemiology
 British Medical Journal
 Clinical Infectious Diseases
 Emerging Infectious Diseases
 Journal of Adolescent Healthcare
 Journal of American Medical Association
 Journal of Clinical Investigation
 Journal of Clinical Microbiology
 Journal of Human Immunology
 Journal of Infectious Diseases
 Journal of Pediatrics
 Journal of Pediatric Infectious Diseases
 Lancet
 New England Journal of Medicine
 Pediatric Infectious Disease Journal
 Pediatrics
 PLoS One
 Vaccine

POST DEGREE HONORS AND AWARDS

1986-1988 Stetler Foundation Postdoctoral Medical Fellowship
 1989 Alexander D. Langmuir Award- Epidemic Intelligence Service Alumni Award, Centers for Disease Control, Atlanta, GA
 1996 Editorial Board, Manual of Control of Communicable Diseases in Man, American Public Health Association
 2001 Multicultural Alumni Hall of Fame, Stanford University
 2003 Stanford University School of Medicine Teaching Commendation
 2008-2018 Berger-Raynolds Distinguished Packard Fellow
 2009- Editorial Board: HIV/AIDS- Research and Palliative Care
 2013- Member, Faculty of 1000, Infectious Diseases
 2017 Distinguished Service Award, Lucile Packard Children's Hospital at Stanford University
 2018 Stanford Medical Alumni RISE (Reach, Inspire, Serve, Engage) Award
 2018 National Hispanic Health Foundation Leadership Award

2020 Stanley A. Plotkin Vaccinology Lectureship Award, Pediatric Infectious Disease Society

STANFORD COURSES DIRECTED:

2003- present Health Research and Policy 231: Epidemiology of Infectious Diseases
2014 – present Human Biology 124c: Global Child Health

Abstracts presented at professional meetings

1. **Maldonado YA**, Hestvik L, Wilson M, O'Hare J, Bi-Wee S, Townsend T, and Yolken R. Safety and Immunogenicity of Vaccination with RIT Rotavirus Strain 4237 in Three-month Old Infants. Presented to the American Pediatric Society & Society for Pediatric Research, 1986.
2. **Maldonado YA**, Nahlen B, Roberto R, Ginsberg M, Orellana E, Mizrahi M, McBarron K, Campbell C. Introduced Plasmodium vivax Malaria, San Diego, California, 1986. Presented at the 1987 Epidemic Intelligence Service Conference, Centers for Disease Control, Atlanta, Georgia, April 1987.
3. **Maldonado YA**, Frain J, Oshiro L, Ho M-S, Glass R. A Cluster of False-Positive Test Results for Rotavirus, California. Presented at the 1987 Epidemic Intelligence Service Conference, Centers for Disease Control, Atlanta, Georgia, April 1987.
4. **Maldonado YA**, Roesch K, Deresinski S, Roberto R. Nosocomial Hepatitis B Associated with a Seronegative Health Care Worker. Presented at the Western Regional Epidemic Intelligence Service Conference, Tucson, Arizona, March 1988.
5. **Maldonado YA**, Schechter GH, Mata A, Neal DP, Lemp GF, Rutherford GW. Epidemiology of Tuberculosis in AIDS Patients, San Francisco. Poster presentation at the Fourth International AIDS Conference, Stockholm, Sweden, June 1988.
6. Aubert, R., **Maldonado YA**. Use of Multiple Cause of Death Data to Estimate AIDS Mortality in California. Poster presentation at the Fourth International AIDS Conference, Stockholm, Sweden, June 1988.
7. Duliege A-M., Wang, E., Singleton, J., **Maldonado YA**. Impact of the HIV Epidemic on the Mortality of Children in California. Poster presentation at the Sixth International Conference on AIDS, San Francisco, CA, June 1990.
8. **Maldonado YA**, Wang E, Sullivan B, Margolis H, Wilson MJ, Hughes M, Oxtoby M. Clinical Spectrum of Perinatally-Acquired Pediatric HIV Infection. Poster presentation at the Sixth International Conference on AIDS, San Francisco, CA, June 1990.
9. **Maldonado YA**, Seavello J, Caldwell B, and The Northern California Pediatric HIV Consortium. Evaluation of HIV Culture and Polymerase Chain Reaction in Perinatal HIV Infection. Oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 1992.
10. Goodman S, Calventi V, Lavendera M, Koenig E, Martin N, **Maldonado YA**. Risk Behavior for HIV Infection among Women of Childbearing Age in the Urban Dominican Republic. Poster presentation at the Eighth International Conference on AIDS, Amsterdam, Netherlands, July 1992.

11. Logan L, Weirich E, Chmyz M, **Maldonado YA**. Lack of Detection of Rotavirus and Adenovirus Types 40 and 41 in Young Infants in a Rural Mexican Village. Poster presentation at the Pan American Group for Rapid Viral Diagnosis, April 1993.
12. Bernal M, Logan L, Weirich E, Lo R, Matsui S, **Maldonado YA**. Viral Diarrhea in a Suburban Day Care Center. Oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, October, 1993.
13. Logan L, Hanagud S, Chmyz M, Sanchez L, **Maldonado YA**. Rapid Identification of Enterovirus Using 4 Cell Lines and a Chemiluminescently Labeled Nucleic Acid Probe. Poster presentation at the Pan American Group for Rapid Viral Diagnosis, April 1994.
14. Logan L, Hanagud S, Chmyz M, **Maldonado YA**. Use of a Chemiluminescent Group Probe for the Detection of Enterovirus from Stool Samples. Poster presentation at the American Society for Microbiology Annual Meeting, Las Vegas, NV, May 1994.
15. Ramos-Gomez F, Hilton J, Canchola A, Greenspan D, Greenspan J, **Maldonado YA**. Risk Factors for HIV-related Orofacial Manifestations in Children. 10th International Conference on AIDS, Yokohama, Japan, August 1994.
16. **Maldonado YA**, Logan L, Hanagud S, Chmyz M, Sanchez L. Shedding of Sabin Strain Poliovirus in Rural Mexican Children After Administration of Oral Polio Vaccine. Oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994.
17. **Maldonado YA**, Logan L, Sanchez M, Chmyz M, Millan F, Valdespino J, Matsui S, Greenberg H. Population-based Prevalence of Astrovirus Gastroenteritis in Rural Mayan Children. Poster presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1995.
18. Weirich E, Rabin RL, Benitz W, Herzenberg L, **Maldonado YA**. CD11b Expression on Neutrophils as a Diagnostic Marker for Neonatal Sepsis. Oral presentation at the Society for Pediatrics Research Annual Meeting, Washington, D.C., May, 1996.
19. **Maldonado YA**, Araneta MRG, Hersh AL, and the Northern California Pediatric HIV Consortium. Effect of Zidovudine and Pneumocystis Carinii Pneumonia Prophylaxis on Early Progression of Perinatal HIV Infection. Oral Presentation presented at the XI International Conference on AIDS, Vancouver, Canada, July, 1996.
20. **Maldonado YA**, Peña V, Sanchez M, Logan L, Millan F, Matsui S, Greenberg H, Valdespino J, Sepulveda J. Factors Affecting the Immunogenicity of Oral Poliovirus Vaccine (OPV) in Rural Mayan Children. Poster presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September, 1996.
21. Wang L, Logan L, Peña V, Sanchez M, Millan F, Valdespino J, Sepulveda J, **Maldonado YA**. No Evidence for Circulation of Wild Type 3 Poliovirus in Rural Mayan Children. Poster presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September, 1996.
22. Gans H, Galinus J, Logan L, DeHovitz R, Arvin A, **Maldonado YA**. Comparison of Antibody and T- cell Responses to Measles Vaccine in Infants Immunized at 6, 9, and 12 Months of Age. Poster

presentation at the Infectious Disease Society of America, New Orleans, September, 1996.

23. Gans H, Galinus J, Logan L DeHovitz R, Arvin A, **Maldonado YA**. Comparison of Antibody and T- cell Responses to Measles Vaccine in Infants Immunized at 6, 9, and 12 Months of Age. Measles Workshop. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, September, 1996.
24. **Maldonado YA**, Araneta MRG, Hersh AL, and the Northern California Pediatric HIV Consortium. Effect of Zidovudine and Pneumocystis Carinii Pneumonia Prophylaxis on Early Progression of Perinatal HIV Infection. Eleventh International Conference on AIDS, Vancouver, BC, Canada, July, 1996.
25. Old MO, **Maldonado YA**. Development of mutant analysis with PCR enzyme cleavage (MAPREC) methods to distinguish nt 472 revertant and nonrevertant Sabin type 3 isolates associated with vaccine associated paralytic poliomyelitis (VAPP) from fecal samples. Presented at the Society for Pediatric Research, New Orleans, May, 1998.
26. Katzenstein DA, Mbizvo M, Gittens T, Zejenah L, Nathoo K, **Maldonado YA**, Hill D. Maternal HIV serum RNA levels predict infant mortality and vertical transmission of subtype-C HIV in Zimbabwe. Poster presentation at the Conference on Global Strategies for the Prevention of HIV transmission from Mothers to Infants, Washington , DC, September, 1997.
27. Hill D, **Maldonado YA**, Castro M, Sullivan B, Ruiz J. Temporal patterns in prenatal HIV testing and perinatal treatment and intervention strategies. Presented at the 12th International Conference on AIDS, Geneva, Switzerland, June, 1998.
28. Sanchez-Palacios C, **Maldonado YA**. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-1) infection among ethnically and geographically diverse Peruvian women. Annual Meeting of the Infectious Disease Society of America, Denver, Colorado, November, 1998.
29. Traynor J, Old M, **Maldonado YA**. The natural history of astrovirus infection in a high prevalence population of rural Mayan infants. Annual Meeting of the Infectious Disease Society of America, Denver, Colorado, November, 1998.
30. Satterfield T, Old M, **Maldonado YA**. Development of guanidine thiocyanate extraction method for isolation of Sabin viruses from human fecal samples. Annual Meeting of the Infectious Disease Society of America, Denver, Colorado, November, 1998.
31. Gans H, Arvin A, Lew-Yasukawa L, Beeler J, DeHovitz R, **Maldonado YA**. Immune responses of 6, 9, and 12 month old infants immunized with measles or mumps vaccine. Keystone Symposium on Vaccines, April, 1999.
32. Hill D, **Maldonado YA**, Sullivan B, and the Northern California Pediatric HIV Consortium. Trends in Northern California population-based regional perinatal HIV exposure and infection, 1990-1995. Annual meeting of the American Pediatric Society and the Society for Pediatric Research, San Francisco, May, 1999.
33. Old MO, Garcia J, Kwock D, Martinez C, **Maldonado YA**. A novel fecal extraction method to identify Sabin vaccine viruses among infants receiving OPV after previous IPV administration. Annual meeting of the American Pediatric Society and the Society for Pediatric Research, San Francisco, May, 1999.

34. Gans H, Arvin A, Lew-Yasukawa L, Beeler J, DeHovitz R, **Maldonado YA**. Immune responses of 6, 9, and 12 month old infants immunized with measles or mumps vaccine and the effects of passive antibodies on these responses. Annual meeting of the American Pediatric Society and the Society for Pediatric Research, San Francisco, May, 1999.
35. Frederick T, Thomas P, Melville S, Ortiz I, Mascola L, Rakusan T, Hsu H, Wilfert C, **Maldonado YA**, Bertolli J. The changing clinical spectrum of HIV infection in children. Presented at the Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, Canada, September, 1999.
36. Shetty A, Coovadia H, **Maldonado YA**, Mirochnick M, and the HIVNET 023 Study Team. HIVNET 023 - A phase I/II study of the safety and plasma concentrations of nevirapine given daily, twice a week or weekly as HIV prophylaxis in breastfeeding infants from birth to 24 weeks in Durban, South Africa and Harare, Zimbabwe. Oral presentation at the Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda, September, 2001.
37. Montgomery E, Kropp R, Hill D, **Maldonado YA**. Results of a needs-assessment to determine the culturally-specific needs of pregnant women to prevent perinatal transmission of HIV in California. Poster presentation at the Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda, September, 2001.
38. Gonah NA, Chipato T, Maponga C, Moyo S, Wells J, Bassett MT, **Maldonado YA**. Acceptability of short-course AZT prevention by HIV infected pregnant women: Should VCT in the antenatal setting be modified? Poster presentation at the Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda, September, 2001.
39. Turnbull JH, Herzenberg LA, **Maldonado YA**. Neutrophil CD11b expression as a novel indicator of acute bacterial infection in infants between 30 days and 12 months of age. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, October, 2001.
40. Castellanos JM, Khan SS, **Maldonado YA**. Household transmission and fecal shedding pattern of oral Sabin Type 3 poliovaccine virus (OPV3). Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, October, 2001.
41. Loyal JK, Hill D, Sullivan B, Ruiz J, **Maldonado YA**. Risk factors for missed identification of HIV infected and their infants. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, October, 2001.
42. Nyoni N, Mateta P, Bassett MT, **Maldonado YA**, Wells J, Katzenstein D, Shetty AK. Feasibility and accuracy of rapid on-site HIV tests in antenatal clinics in urban Zimbabwe. Presented as poster during the XIV International AIDS Conference in Barcelona, Spain July 7-12, 2002.
43. Hill DW, Sullivan B, Olson C, Ruiz J, **Maldonado YA**. Population-based survival in perinatal HIV infection before and after PACTG 076.
44. Loyal JK, Hill D, Sullivan B, Ruiz J, **Maldonado YA**. Temporal and demographic trends in identification of HIV-infected woman and their 4 children in California, 1988-1998. Presented as poster during the XIV International AIDS Conference in Barcelona, Spain July 7-12, 2002.

45. Moyo S, Shetty AK, Wells J, **Maldonado YA**, Mhazo M, Katzenstein D, Bassett MT. Experience and concerns of HIV infected women enrolled in MTCT program in Zimbabwe. Presented as poster during the XIV International AIDS Conference in Barcelona, Spain July 7-12, 2002.
46. Strannix LJ, Chibanda D, ChingonoA, Montgomery ET, Wells J, **Maldonado YA**, Bassett MT, Hill DW, Chipato T, Shetty AK. Prevalence of common mental disorder in HIV-positive pregnant women in Zimbabwe. Presented as poster during the XIV International AIDS Conference in Barcelona, Spain July 7- 12, 2002.
47. Moyo S, Mhazo M, Mateta P, von Lieven A, Shetty AK, **Maldonado YA**, Maponga C, Katzenstein D, Bassett MT. Feasibility of HIV/AIDS counseling for pregnant women using community volunteers: experience from Zimbabwe. Presented as poster during the XIV International AIDS Conference in Barcelona, Spain July 7-12, 2002.
48. Montgomery ET, Kropp R, Hill DW, Ruiz J, **Maldonado YA**. Assessment of universal HIV voluntary counseling, test offering and testing for prenatal women in California. Presented as an oral presentation during the XIV International AIDS Conference in Barcelona, Spain July 7-12, 2002.
49. Sarnquist C, Sullivan B, Hill DW, **Maldonado YA**. Implementation and evaluation of interventions aimed at increasing HIV counseling and testing and test acceptance among pregnant women in California. Presented as an Oral presentation during the 130th Annual APHA Meeting in Philadelphia, PA, 9-13 November 2002.
50. Kropp R, Montgomery ET, Hill DW, Ruiz J, **Maldonado YA**. A needs assessment reveals unique challenges to preventing perinatal HIV transmission among Hispanic women in California. Presented as and oral presentation during the 130th Annual APHA Meeting in Philadelphia, PA, 9-13 November 2002.
51. Sansom S, **Maldonado YA**, Ruiz J. Evaluating the impact of programs to increase voluntary HIV testing among pregnant women. Presented as poster during the 130th Annual APHA Meeting in Philadelphia, PA, 9-13 November 2002.
52. Martinez CV, Old MO, Kwock DK, Khan SS, Garcia JJ, Chan CS, Webster R, Falkovitz-Halpern MS, **Maldonado YA**. Shedding of Sabin poliovirus type 3 containing the nt-472 U to C point mutation after administration of oral poliovirus vaccine. Oral presentation, 41st Annual Meeting, Infectious Diseases Society of America, San Diego, CA, October 11, 2003.
53. Jackson DD, **Maldonado YA**, Chan C, Rivas-Merelles E, Santos-Preciado J. Household transmission of atypical isolates of type 3 oral poliovirus vaccine. Poster presentation, 41st Annual Meeting, Infectious Diseases Society of America, San Diego, CA, October 11, 2003.
54. Berk DR, Falkovitz-Halpern MS, Hill DW, **Maldonado YA**. Temporal trends in early clinical manifestations of Perinatal human immunodeficiency virus infection in a population-based cohort. Presented at the Meeting of the Pediatric Academic Societies, Washington DC, May 2005.
55. Wong LJ, Biswas S, Gnanashanmugam D, Fang M, Hammon R, Rivas-Merelles EE, Santos JI, **Maldonado YA**. Shedding and Household Transmission of Sabin Poliovirus Type 3 after administration of OPV to Mexican infants in a primary OPV vaccination schedule. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA), October 6, 2005, San Francisco,

California.

56. Gnanashanmugam D, Fang M, Falkovitz- Halpern MS, Dodge A, Esparza M, Hammon R, Wong LJ, Rivas-Merelles EE, Santos JI, **Maldonado YA**. Comparison of MAPREC to a Real Time PCR Assay Estimating VAPP Reversion of OPV3 in Mexican Families. Presented at the Meeting of the Pediatric Academic Societies, San Francisco, CA, May 2006.
57. Bowles M, Sarnquist C, Falkovitz-Halpern, **Maldonado YA**. Racial/ethnic birth weight and prenatal care disparities in California from 2000-2004. Accepted for presentation at the 134th Annual Meeting, American Public Health Association, November 8, 2006, Boston, MA.
58. Hillary L Copp Hillary, Halpern Meira, **Maldonado YA**, Shortliffe Linda. The Prevalence Of Hospitalization For Pyelonephritis In California Increases: Results from a Statewide Hospital Discharge Database with Implications on a National Scale. Poster presentation, American Urological Association National Meeting, Chicago, Il, April 25-30, 2009.
59. McNeil C, **Maldonado, YA**. California Female Human Papillomavirus Related Anogenital Malignancies. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 21 - 24, 2010 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada.
60. Sarnquist C, **Maldonado YA**. Vaccine Risk Communication: The Role of Resident Education. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 21 - 24, 2010 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada.
61. Sturt A, **Maldonado YA**. Relationship of Pediatric HIV CDC Category B Diagnoses to Progression to Category C Diagnosis and Death. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 21 - 24, 2010 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada.
63. Hoosen Coovadia, EB, **Maldonado YA**, Mofenson L, Moodley D, Musoke P, Fowler MG, Karim Manji, George K, Zwierski S, and the HPTN 046 Protocol Team. HPTN 046: Efficacy of Extended Daily Infant Nevirapine through Age 6 Months Compared to 6 Weeks for Prevention of Postnatal Mother-to-Child Transmission of HIV through Breastfeeding. Oral presentation, Conference on Retroviruses and Opportunistic Infections, Boston, MA, March 2, 2011.
64. Troy SB, Musingwini G, Huang CH, Meira S. Halpern MS, Stranix-Chibanda L, Shetty AK Chirara M, Nathoo K **Maldonado YA**. Oral Polio Vaccine Shedding in HIV-Infected versus Uninfected Zimbabwean Infants. Poster Presentation, 49th Annual Meeting of the Infectious Disease Society of America Boston, MA, October 20-23, 2011.
65. Troy S, Ferreyra-Reyes L, Canizales-Quintero S, Huang CH, Lee YJ, Báez-Saldaña R, Ferreira-Guerrero E, García-García L, **Maldonado YA**. Oral Polio Vaccine Circulation and Mutation after Mexican National Immunization Weeks. Poster Presentation, 49th Annual Meeting of the Infectious Disease Society of America, Boston, MA, October 20-23, 2011.
66. Sturt A, Anglemyer A, Berk D, **Maldonado YA**. Pediatric HIV CDC Category A and B Dermatologic Diagnoses over 22 Years of Longitudinal Follow-up. (manuscript title: temporal trends in

mucocutaneous finding among human immunodeficiency virus-1 infected children in a population-based cohort). Poster Presentation, 49th Annual Meeting of the Infectious Disease Society of America, Boston, MA, October 20-23, 2011.

67. Sarnquist C, Stranix-Chibanda L, Moyo P, Tagwera V, Chipato T, Kang J, **Maldonado YA**. Integrating family planning into prevention of mother-to-child HIV transmission (PMTCT) programs: Maximizing PMTCT in Zimbabwe. Poster presentation, 19th International AIDS Conference, July 22-27, 2012. Washington, DC.
68. Troy S, Nathoo K, Stranix-Chibanda L, Shetty A, Musingwini G, Huang CH, Holubar M, Halpern, M, **Maldonado Y**. The Effects of HIV Exposure and Malnutrition on Oral Polio Vaccine Shedding in Zimbabwean Infants. Poster Presentation. 50th IDWeek, San Diego, CA, October 16-21, 2012.
69. Holubar M, Troy S, Kusum Nathoo K, Stranix-Chibanda, L, Shetty A, Musingwini G, Huang C, Srinivas N, Halpern M, Maldonado Y. Shedding of Oral Polio Vaccine (OPV) in Mothers of OPV-vaccinated Zimbabwean Infants. Poster Presentation. 50th IDWeek, San Diego, CA, October 16-21, 2012.
70. Ferreyra-Reyes L, Canizales-Quintero S, Nelson C, Huang CH, Baez- Saldana R, Ferreira-Guerrero E, Garcia-Garcia L, **Maldonado, Y**. Oral Polio Vaccine Shedding among Mexican Children after National Immunization Weeks. Poster Presentation. 50th IDWeek, San Diego, CA, October 16-21, 2012.
71. Dyner LL, Yasukawa LL, Sung P, Mason P, Nathoo K, Hayley Gans, H, **Maldonado Y**. Immunogenicity of the Measles Vaccine in HIV-infected and HIV-exposed Uninfected Infants in Zimbabwe. Poster Presentation. 50th IDWeek, San Diego, CA, October 16-21, 2012.
72. Stranix- Chibanda L, Chipato T, **Maldonado Y**. Efficacy and safety of 6 months vs 6 weeks nevirapine (NVP) for prevention of postnatal HIV-1 transmission 18 month follow-up of the HPTN 046 trial. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013. Atlanta, GA.
73. Troy S, Ferreyra-Reyes L, Huang CH, Canizales-Quintero S, Nelson C, Baez-Salada R, Elizabeth Ferreira-Guerrero E, Garcia-Garcia L, **Maldonado Y**. Differential Circulation Patterns of Oral Polio Vaccine Serotypes 1, 2, and 3 after Mexican National Immunization Weeks. Oral Abstract Presentation. 51st IDWeek, San Francisco, CA, October 2-6, 2013.
74. Kann D, Norton E, Bauer D, Huang CH, Clements J, **Maldonado Y**. Fecal Markers of Intestinal Immunity Using a Poliovirus Vaccine Model. Poster Abstract Presentation. 53rd IDWeek, San Diego, CA, October 7-11, 2015.
75. Sarnquist C, Holubar M, Garcia-Garcia L, Ferreyra Reyes, L, Montero-Campos R, Cruz-Hervert LP, Talib A, Falkovitz Halpern M, **Maldonado Y**. Towards Polio Eradication: OPV and IPV exposure in Mexican Communities Preparing for a Randomized Controlled Trial of Poliovirus Circulation Patterns. Poster Abstract Presentation. 53rd IDWeek, San Diego, CA, October 7-11, 2015.
76. Huang CC, Holubar M, Leary S, Hoorebeke C, **Maldonado Y**. Use of a High-Throughput, Multiplex Assay for Detection of Sabin Oral Polio Vaccine in Fecal Samples. Poster Abstract Presentation. Pediatric Academic Societies Annual Meeting, Baltimore, MD, April 30-May 3, 2016.
77. Cruz-Hervert LP, Ferreyra Reyes L, Canizales-Quintero S, Montero-Campos R, Delgado G, Ferreira E, Mongua N, Melchor A, Sarnquist C, Holubar M, Talib A, Altamirano J, **Maldonado Y**, Garcia-Garcia L Determinants of IPV Vaccination Among Children Younger Than Five in Three Rural

and Semiurban Communities in Mexico. Poster Abstract Presentation. Pediatric Academic Societies Annual Meeting, Baltimore, MD, April 30-May 3, 2016.

78. Sarnquist CC, Garcia-Garcia L, Ferreyra L, Montero-Campos R, Cruz-Hervert LP, Altamirano J, Holubar M, Talib A, Purington N, Halpern M, Ferreira E, Delgado G, Canizales Quintero S, **Maldonado Y**. Preventing Polio Post-eradication: Elucidating Polio Virus Shedding and Transmission Patterns in the Presence of IPV and OPV. Oral Presentation, 54th IDWeek, New Orleans, LA, October 26-30, 2-16, 2016.

79. Kann D, **Maldonado Y**. Total and Polio Specific Fecal IgA Trends in a Pediatric Cohort Poster Presentation, 54th IDWeek, New Orleans, LA, October 26-30, 2-16, 2016

80. Anglemeyer A, Sturt A, **Maldonado Y**. The Effect of Antiretroviral Therapy Use Among HIV-1 Positive Children on the Hazard of AIDS Using Calendar Year as an Instrumental Variable. Poster Presentation, 54th IDWeek, New Orleans, LA, October 26-30, 2-16, 2016.

81. Jarvis C, Edmunds J, Altamirano J, **Maldonado Y**. OPV transmissibility in communities after cessation of routine OPV immunization: GPS analysis. Oral Presentation, 55th IDWeek, San Diego, CA, October 4-8, 2017.

Selected invited lectures

1. Epidemiology of Pediatric AIDS. University of California at Berkeley School of Public Health. February 18, 1992

2. HIV Disease in Latinos. California Latino Health Care Task Force. March 7, 1992

3. Pediatric HIV. University of New Mexico Pediatric Grand Rounds. May 21, 1992

4. Pediatric Vaccines. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. September 11, 1992

5. Epidemiology of HIV in Infants and Children. Hospital Infantil de Mexico Grand Rounds, Mexico City. November 19, 1992

6. Measles Vaccine: State of the Art. 18th Annual Meeting of the Mexican Infectious Disease Society, Mexico City. November 22, 1993

7. Epidemiology of Pediatric HIV. Third Annual Update on AIDS Conference, San Francisco, California. May 20, 1994

8. Pediatric AIDS. Lucile Salter Packard Children's Hospital at Stanford Plenary Session, Continuing Medical Education Course. July 16, 1994

9. Epidemiology of Poliovirus infection in the Western Hemisphere. Invited lecture, National Institutes of Health, Bethesda, Maryland. September 29, 1994.

10. Antiviral Agents. Plenary Session, American Academy of Pediatrics Annual Meeting, Dallas, Texas. October 23, 1994

11. Principles of Hospital Infection Control. Association for Practitioners of Infection Control, Asilomar, California. November 10, 1994
12. Pneumococcal Infections. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. May 26, 1995
13. Intensive review of Pediatric Infectious Diseases. PREP the Course (National Pediatrics Review and Education Program, American Academy of Pediatrics), Santa Monica, California. February 3 - 7, 1995
14. Intensive review of Pediatric Infectious Diseases. PREP the Course (National Pediatrics Review and Education Program, American Academy of Pediatrics), Minneapolis, Minnesota. August 12-16, 1995
15. How to Conduct Clinical Trials. Plenary Session jointly sponsored by the Infectious Disease Society of America, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Food and Drug Administration, San Francisco, California. September 15, 1995
16. Antivirals and Antibiotics. Plenary Session, American Academy of Pediatrics Annual Meeting, San Francisco, California. October 15, 1995
17. Varicella Virus and Chickenpox Vaccine. American Society for Microbiology, Concord, California. November 11, 1995
18. Pediatric HIV Infection: Maternal and Infant Prevention and Management. California Department of Health Services Fifth Annual Governor's Conference. San Diego, California. February 5, 1998.
19. Clinical Management of HIV in Newborns: Mothers to be and Newborns. Thirteenth Annual Conference on Human Retrovirus Testing, San Diego, California. March 4, 1998.
20. Update on Pediatric Vaccines. Pediatric Grand Rounds, University of California, San Francisco. May, 1998.
21. What's New in Viral Vaccines. Polio and the Eradication effort. Medical Virology Symposium, Annual meeting of the American Society for Virology. Vancouver, British Columbia, Canada. July 11, 1998.
22. Infectious Diseases in Children: Successes and Failures in Lowering Morbidity and Mortality in Africa and Latin America. The Environmental Policy Forum, Institute for International Studies, Stanford University, December 3, 1998.
23. Measles Vaccine Efficacy. Aerosol Measles Immunization and Alternative Routes of Immunization Workshop. A.B. Sabin Vaccine Institute, Georgetown University, Washington, DC, January 13, 1999.
24. Clinical Trials and Universities. "The FDA Comes to Stanford." Stanford University, March 23, 2000.
25. Elimination of Measles in the United States. Meeting of the National Vaccine Advisory Committee, United States Public Health Service, Washington, DC, October 24, 2000.

26. Edmonston B Measles Vaccine Administration to the Yanomami Indians. Meeting of the American Anthropologic Association, San Francisco, California, November 16, 2000.
27. HIV/AIDS among African American Women in California. African Americans: Meeting the Challenge to Protect the Future. UC Davis Fifth Annual AIDS Conference, Sacramento, California, October 19, 2001.
28. Household Transmission of Oral Poliovirus Vaccine: Implications for Eradication. University of California at Berkeley School of Public Health, November 2, 2001.
29. Adaptive Immunity of Young Infants to Measles and Mumps Vaccine. WHO Steering Committee on research related to measles vaccines and vaccination, March 27-28, 2002, WHO, Geneva.
30. OPV and IPV Studies in Mexico. Meeting of the Mexican Federal Health Department and World Health Organization on "Poliomyelitis: an update in the Mexican Context." Cancun, Mexico, March 4, 2004.
31. Approach to Rotavirus Gastroenteritis. Pediatric Grand Rounds, USC County Medical Center, Los Angeles, California, July 18, 2006.
32. Global Childhood Survival: How Preventable Infections in the Developing World Affect Us All. Meeting of the Zimbabwe Pediatric Association, Harare, Zimbabwe, August 9, 2006.
33. Pediatric HIV and AIDS efforts and the UN Millenium Program. Can the United Nations Save the World? Symposium at Stanford University School of Medicine, Stanford, CA, October, 2006.
34. HPV Infection and HPV Vaccine. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. March 5, 2007
35. Impact of Fetal and Neonatal viral (and Parasitic) infections on later development and diseases outcome. The Window of Opportunity: Pre-Pregnancy to 24 Months of Age, volume 61 of the Nestlé Nutrition Workshop Series. April 1-5, 2007, Bali, Indonesia.
36. MRSA Colonization and Infection: Implications for Pediatrics. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. December 14, 2007
38. Emerging Issues in Pediatric Foodborne Illness. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. September 5, 2008.
39. MRSA. Eden Valley Medical Center Grand Rounds. December 19, 2008.
40. Hacia la eliminación del sarampión en México y en el continente Americano. 13 Congreso de Investigacion en Salud Publica-INSP, Instituto Nacional de Salud Publica, Cuernavaca, Mexico, March 5, 2009.
41. An update on Human Papillomavirus. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. January 16, 2009.
42. Routine Use of RotaTeq®:Postlicensure Experience in US. Plenary session, World Society of Pediatric Infectious Diseases, Buenos Aires, Argentina, November 21, 2009.

43. Postlicensure Experience with Oral, Pentavalent Rotavirus Vaccine (RotaTeq[®]). Plenary Session, International Pediatric Association (IPA) Congress of Pediatrics, Johannesburg, South Africa, August 4, 2010.
44. Rotavirus Vaccination and Human Papilloma Virus (HPV) Vaccination. Plenary Session, Biennial meeting, Turkish Pediatric Infectious Diseases Congress, Antalya, Turkey, April 28, 2011.
45. Safety and Effectiveness of Oral, Pentavalent Rotavirus Vaccine (RotaTeq[®]). Plenary Session, Annual Meeting, Sociedad Latinoamericana de Infectiología Pediátrica, Punta Cana, Dominican Republic, May 27, 2011.
46. HPTN 046: Efficacy of Extended Daily Infant Nevirapine through Age 6 Months Compared to 6 Weeks for Prevention of Postnatal Mother-to-Child Transmission of HIV through Breastfeeding. Plenary talk, HIV Prevention Trials Network/ International Maternal Pediatric Adolescent AIDS Clinical Trials Group Annual retreat, Washington DC, June 8, 2011.
47. Pediatric Vaccine Update 2011. Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. September 30, 2011.
48. Pediatric HIV Infection: A Global Perspective. Keynote Address, Sanford/Mayo Symposium, Inaugural Denny Sanford Visiting Professor, November 4, 2011, Sanford Medical School, Sioux Falls, South Dakota.
49. Measles vaccines - A positive step toward eradicating a negative strand. Grand Rounds, Merck & Co., November 15, 2011. West Point, Pennsylvania.
50. Global childhood survival: Pediatric infectious disease challenges. Research seminar, Children's Hospital at Los Angeles, December 14, 2011. Los Angeles, California.
51. Pediatric IPV and OPV studies in Zimbabwe and Mexico. Polio Research Committee meeting, World Health Organization, Geneva, Switzerland, April 3, 2012.
52. Panorama de poliomyelitis y riesgo de re-emergencia (Poliomyelitis panorama and risk of reemergence). 35th annual meeting of the Mexican Association of Infectology and Microbiology (AMIMC) April 26, 2012. Leon, Guanajuato, Mexico
53. Global Childhood Survival: Vaccine Preventable Deaths. American Academy of Pediatrics Global Vaccine Advisory Committee, US Congressional briefing, June 13, 2012, Washington DC.
54. Pertussis and Pertussis Vaccine Update. 12th Annual Stephen A. Chartrand, M.D. Memorial Distinguished Lecture, Department of Pediatrics, Creighton University School of Medicine, Omaha, Nebraska, September 28, 2012.
55. Panorama de poliomyelitis y riesgo de re-emergencia (Poliomyelitis panorama and risk of re emergence). XVI Congreso Latinoamericano de Pediatría – ALAPE 2012. November 17, 2012. Cartagena, Colombia.
56. La tos ferina y actualización de la vacuna de tos ferina (Pertussis and update on pertussis vaccine). XVI Congreso Latinoamericano de Pediatría- ALAPE 2012 November 17, 2012, Cartagena,

Colombis.

57. Epidemiologic Principles in the Global Elimination of Poliomyelitis. MAC-EPID symposium "Eradicating Polio: Scientific Opinion and Political Will." November 13, 2015, University of Michigan School of Public Health, Ann Arbor, Michigan.

58. The American Academy of Pediatrics & Global Immunizations. WHO/Sabin Institute Joint Symposium on Closing Immunity Gaps in Older Children and Adults Towards Measles and Rubella Elimination: Lessons learned and challenges. Siena, Italy 10-11 May 2016.

59. Bay Area Virus Symposium Plenary talk. Epidemiologic Principles in the Global Elimination of Poliomyelitis. UC Berkeley, California, May 2, 2016.

60. Red Book 2016 Vaccine Update. William E. Rhea Memorial Lectureship. July 26, 2016, UCSF Benioff Oakland Children's Hospital.

61. Efficacy and effectiveness of RotaTeq™: results from pre-licensure and post-marketing studies. September 14, 2017, the 1st International Gastroenteritis Workshop, Fudan University, Shanghai, China.

62. Pediatric Immunization Update. Bay Area Infectious Disease Conference for Prenatal and Pediatric Providers. January 24, 2018, Alameda County Health Department, Oakland, California.

63. SPHERE: Collaborative Research and Precision Medicine. 17th Annual Developmental Disabilities: An Update for Health Professionals 2018. March 8, 2018, University of California, San Francisco, California.

64. Dealing with Vaccine Hesitancy. July 12, 2018, Philippine Pediatric Society, Manila, Philippines.

65. Temas para el final de la erradicación de la polio y las limitaciones de la inmunogenicidad de la OPV y la IPV. August 3, 2018, Department of Immunology, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.

66. Academic Biomedical Career Customization (ABCC) Promoting Flexibility in Academic Medicine to Foster Success. August 10, 2018, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri.

67. Global Climate Change: Infectious Diseases and Impact on Child Health. Children's' Health and Climate Change. Global Climate Action Summit, September 13, 2018, San Francisco, California.

68. Maternal HBV Viremia is associated with adverse infant outcomes in HIV/HBV women. March 4-7, 2019, 2019 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington.

69. Novel Coronavirus (COVID-19) Update. May 7, 2020, Department of Pediatrics, Staten Island University Hospital, Staten Island, New York.

70. Redbook Update. May 8, 2020, Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. January 16, 2009.

69. Using COVID-19 Epidemiology to Understand When and How to Return to Work and School. June 5, 2020, Lucile Salter Packard Children's Hospital at Stanford Grand Rounds. January 16, 2009.

Memberships in professional associations and learned societies

1983-1987 Junior Fellow, American Academy of Pediatrics
 1988- Fellow, American Academy of Pediatrics
 1989- Member, Infectious Disease Society of America
 1996- Member, Pediatric Infectious Disease Society
 1996- Member, Infectious Disease Section, Northern California Chapter, American Academy of Pediatrics
 2000-2004 Co-Chair, Infectious Disease Section, Northern California Chapter, American Academy of Pediatrics
 2002- Member, American Public Health Association
 2006- Member, American Pediatric Society
 2006- Member, American Society of Microbiology
 2010- Member, Society of Healthcare Epidemiology of American
 2015- Fellow, Pediatric Infectious Diseases Society

Certification

1984-1988 State of Maryland Medical License
 1988- State of California Medical License G63684
 1988- Board Certification in Pediatrics, American Board of Pediatrics

II. Bibliographic information**A.1. Scholarly publications****Articles published in peer-reviewed professional journals**

1. Goldblum OR, Brusilow SW, **Maldonado YA**, Farmer ER. Neonatal citrullinemia associated with cutaneous manifestations and arginine deficiency. Journal of the American Academy of Dermatology. 2:321- 6, 1986.
2. **Maldonado YA**, Hestvik L, Wilson M, O'Hare J, Bi-Wee S, Townsend T, Yolken R. Safety and Immunogenicity of Bovine Rotavirus Vaccine RIT 4237 in 3-month-old Infants. Journal of Pediatrics. 109:931-5, 1986.
3. Shaw RD, Fong KJ, Losonsky GA, Levine MM, **Maldonado YA**, Yolken R, Flores J, Kapikian AZ, Vo PT, Greenberg HB. Epitope-Specific Immune Responses to Rotavirus Vaccination. Gastroenterology. 93:941-50, 1987.
4. **Maldonado YA**, Nahlen BL, Roberto RR, Ginsberg M, Orellana E, Mizrahi M, McBarron K, Lobel HO, Campbell CC. Transmission of Plasmodium vivax Malaria in San Diego County, California, 1986. American Journal of Tropical Medicine and Hygiene. 42:3-9, 1990.
5. Yolken RH, **Maldonado YA**, Kinney J, Vonderfecht S. Epidemiology and Potential Methods for Prevention of Neonatal Intestinal Viral Infections. Reviews of Infectious Diseases. 12:S421-7, 1990.

6. Caldwell BM, Mascola L, Smith W, Thomas P, Hsu HW, **Maldonado YA**. Parents-Biologic, Foster, and Adoptive: Caregivers of Children Exposed Perinatally to HIV in the United States. Pediatrics. 90:603- 11, 1992.
7. St. Geme JW, **Maldonado YA**, Enzmann D, Hotez P J, Overturf GD, Schantz PM. Consensus: Diagnosis and Management of Neurocysticercosis in Children. Pediatric Infectious Disease Journal. 12:455- 61, 1993.
8. Lesar S, **Maldonado YA**. Infants and Young Children with HIV Infection: Service Delivery Considerations for Family Support. Infants and Young Children. 6:70-81, 1994.
9. **Maldonado YA**, Wang NE, Caldwell B, and the Northern California Pediatric HIV Consortium. Factors Associated with Early Clinical Recognition of Children with Perinatal Human Immunodeficiency Virus Infection. Journal of Infectious Diseases. 171:689-92, 1995.
10. **Maldonado YA**, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early Loss of Passive Measles Antibody in Infants of Mothers with Vaccine-Induced Immunity. Pediatrics. 96:447-50, 1995.
11. Rabin RL, Roederer M, **Maldonado YA**, Petru A, Herzenberg LA, Herzenberg LA. Altered Representation of Naive and Memory CD8 T Cell Subsets in HIV-Infected Children. Journal of Clinical Investigation. 95:2054-60, 1995.
12. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, Anderson E, Bernstein D, Ward R, Chartrand S, Cherry J, Blumberg D, Davidson B, Zito E, Mack M, Forro J, Camardo J, Starr E, Dennehy P, Fries S, Froehlich H, Glass R, Hamm C, Imrie R, Jackson M, Kim K, Guzman E, Levin M, **Maldonado Y**, Pichichero M, Pickering L, Pomeranz A, Rennels M, Keane V, Rodgers G, Rabalais G, Sack D, Said D, Singh-Naz N, Pedreira F, van Dyke R, Wald E. Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children. JAMA. 1995;273:1191-6.
13. Lesar S, **Maldonado YA**. Parental Coping Strategies in Families of HIV-infected Children. Children's Health Care Journal. 25:19-35, 1996.
14. Barnhart H, Caldwell B, Thomas P, Mascola L, Ortiz I, Hsu H, Schulte J, Parrott R, **Maldonado YA**, Byers R and the Pediatric Spectrum of Disease Clinical Consortium. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics. 97:710-6, 1996.
15. Morris C, Araba-Owoyele L, Spector SA, **Maldonado YA**. Disease Patterns and Survival after AIDS Diagnosis in HIV-Infected Children. Pediatric Infectious Disease Journal. 15:321-8, 1996.
16. Ramos-Gomez FJ, Hilton JF, Canchola AJ, Greenspan D, Greenspan JS, **Maldonado YA**. Risk Factors for HIV-Related Soft Tissue Orofacial Manifestations in Children. Pediatric Dentistry. 18:121-6, 1996.
17. **Maldonado YA**, Peña-Cruz V, Sanchez M, Cantwell M, Logan L, Blandón S, Matsui S, Millan-Velasco F, Valdespino JL, Sepulveda J. Host and Viral Factors Affecting the Decreased Immunogenicity of

Sabin Type 3 After Administration of Trivalent Oral Polio Vaccine (OPV) to Rural Mayan Children. Journal of Infectious Diseases. 175:545-53, 1997.

18. Lesar S, **Maldonado YA**. The Impact of children with HIV-Infection on the Family System. Families in Society. 78:272-9, 1997.

19. Old MO, Logan LH, **Maldonado YA**. Development of chemiluminescent probe hybridization, RT-PCR and nucleic acid cycle sequencing assays of Sabin type 3 isolates to identify base pair 472 Sabin type 3 mutants associated with vaccine-associated paralytic poliomyelitis. Journal of Virological Methods. 68:109-18, 1997.

20. Weirich E, Rabin RL, **Maldonado YA**, Benitz W, Modeler S, Herzenberg LA, Herzenberg LA. CD11b Expression on Neutrophils as a Diagnostic Marker for Neonatal Infection. Journal of Pediatrics. 132:445-51, 1998.

21. **Maldonado YA**, Araneta MRG, Hersh AL, and the Northern California Pediatric HIV Consortium. Effect of Pneumocystis Carinii Pneumonia Prophylaxis and Zidovudine on the Natural History of Early Progression of Perinatal Human Immunodeficiency Virus Infection. Pediatric Infectious Disease Journal. 17:398-402, 1998.

22. Gans H, Galinus J, Logan L, DeHovitz R, Arvin A, **Maldonado YA**. Comparison of Antibody and T-cell Responses to Measles Vaccine in Infants Immunized at 6, 9, and 12 Months of Age. Journal of the American Medical Association. 280:527-32, 1998.

23. **Maldonado YA**, Cantwell M, Logan L, Sanchez M, Millan F, Valdespino J, Sepulveda J, Matsui S. Population-based Prevalence of Astrovirus Gastroenteritis in Rural Mayan Infants. Journal of Infectious Diseases. 178:334-9, 1998.

24. Zijenah L, Mbizvo MT, Kasule J, Nathoo K, Munjoma M, Mahomed K, **Maldonado YA**, Madzime S, Katzenstein D. Mortality in the first two years among infants born to HIV-infected women in Harare, Zimbabwe. Journal of Infectious Diseases. 178:109-13, 1998.

25. Granich R, Cantwell MF, Long K, **Maldonado YA**, Parsonnet J. Patterns of health seeking behavior during episodes of childhood diarrhea: a study of Tzotzil-speaking Mayans in the highlands of Chiapas, Mexico. Social Science & Medicine. 48:489-95, 1999.

26. Gans HA, **Maldonado YA**, Yasukawa LL, Beeler J, Audet S, Rinki MM, DeHovitz R, Arvin AM. Interleukin 12, interferon gamma and T cell proliferation to measles in immunized infants. Journal of Immunology. 162:5569-75, 1999.

27. Gutierrez KM, Halpern MF, **Maldonado YA**, Arvin AM. The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. Journal of Infectious Diseases. 180:199-202, 1999.

28. Katzenstein DA, Mbizvo M, Zijenah L, Gittens T, Munjoma M, Hill D, Madzime S, **Maldonado YA**. Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. Journal of Infectious Diseases. 179:1382-7, 1999.

29. Peter G, des Vignes-Kendrick M, Eickhoff TC, Fine A, Galvin V, Levine MM, **Maldonado YA**, Marcuse EK, Monath TP, Osborn JE, et al. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics. 104(4 Pt 1):942-50, 1999.
30. The National Vaccine Advisory Committee (**Maldonado YA** as a member of the Committee). Strategies to sustain success in childhood immunizations. Journal of the American Medical Association. 282:363-70, 1999.
31. Dominguez K, Bertolli J, Fowler M, d'Almada P, Peters V, Ortiz I, Melville S, Rakusan T, Frederick T, Hsu H, **Maldonado YA**, Wilfert C, the PSD Consortium and the Perinatal Safety Review Working Group. Lack of Definitive Severe Mitochondrial Signs and Symptoms among Deceased HIV-Uninfected and HIV- Indeterminate Children 5 Years of Age, Pediatric Spectrum of HIV Disease Project (PSD), USA. Annals of the New York Academy of Sciences. 918:236-246, 2000.
32. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, **Maldonado YA**, Arvin AM. Immune Responses to measles and mumps vaccination of infants at 6, 9, and 12 months. Journal of Infectious Diseases. 184:817-26, 2001.
33. Shetty AK, Frankel LR, **Maldonado YA**, Falco DA, Lewis DB. Group A streptococcal meningitis: report of a case and review of literature since 1976. Pediatric Emergency Care. 17:430-4, 2001.
34. **Maldonado YA**. Current Controversies in Vaccination: Vaccine Safety. Journal of the American Medical Association. 288:3155-8, 2002.
35. Old MA, Martinez CV, Kwock D, Garcia J, Martin G, Chan C, **Maldonado YA**. Direct extraction of Sabin poliovirus genomes from human fecal samples using a novel guanidine thiocyanate extraction method. Journal of Virological Methods. 110:193-200, 2003.
36. Sanchez-Palacios C, Gotuzzo E, Vandamme AM, **Maldonado YA**. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. International Journal of Infectious Diseases. 7:132-7, 2003.
37. Shetty AK, **Maldonado YA**. Preventing mother-to-child transmission of human immunodeficiency virus type 1 in resource-poor countries. Pediatric Infectious Disease Journal. 22:553-5, 2003.
38. Gans H, DeHovitz R, Forghani B, Beeler J, **Maldonado YA**, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine. 21: 3398-405, 2003.
39. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. Shetty AK, Coovadia HM, Mirochnick MM, **Maldonado YA**, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT; HIVNET 023 Study Team. Journal of Acquired Immune Deficiency Syndromes. 34:482-90, 2003.
40. Gottlieb D, Shetty AK, Mapfungautsi RM, Bassett MT, **Maldonado YA**, Katzenstein DA. Infant Feeding Practices of HIV-infected and uninfected women in Zimbabwe. AIDS Patient Care and

STDS.18:45-53, 2004.

41. Wong-Chew RM, Islas-Romero R, Garcia-Garcia Mde L, Beeler JA, Audet S, Santos-Preciado JJ, Gans H, Lew-Yasukawa L, **Maldonado YA**, Arvin AM, Valdespino-Gomez JL. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. Journal of Infectious Diseases.189:254-7, 2004.
42. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, **Maldonado YA**, Arvin AM. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. Journal of Infectious Diseases. 190:83-90, 2004.
43. Gans HA, Yasukawa LL, Alderson A, Rinki M, Dehovitz R, **Maldonado YA**, Arvin AM. T cell immunity to measles viral proteins in infants and adults after measles immunization. Viral Immunology. 17:298-307, 2004.
44. Martinez CV, Old MO, Kwock DK, Khan SS, Garcia JJ, Chan CS, Webster R, Falkovitz-Halpern MS, **Maldonado YA**. Shedding of Sabin poliovirus Type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. Journal of Infectious Diseases.190:409-16, 2004.
45. Kropp RY, Montgomery ET, Hill DW, Ruiz JD, **Maldonado YA**. Unique challenges to preventing perinatal HIV transmission among Hispanic women in California: results of a needs assessment. AIDS Education and Prevention.17:22-40, 2005.
46. Berk DR, Falkovitz-Halpern MS, Hill DW, **Maldonado YA**. Temporal trends in early clinical manifestations of Perinatal human immunodeficiency virus infection in a population-based cohort. Journal of American Medical Association. 293:2221-31, 2005.
47. Glass RI, Bhan MK, Ray P, Bahl R, Parashar UD, Greenberg H, Rao CD, Bhandari N, **Maldonado YA**, Ward RL, Bernstein DI, and Gentsch JR. Development of candidate rotavirus vaccines derived from neonatal strains in India. Journal of Infectious Diseases. 192 Suppl 1:S30-5, 2005.
48. Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H, **Maldonado YA**, Adeniyi Jones S, Mofenson LM, Contag CH, Bassett M, Katzenstein DA. Breast-Milk Shedding of Drug-Resistant HIV-1 Subtype C in Women Exposed to Single-Dose Nevirapine. Journal of Infectious Diseases. 192:1260-4, 2005.
49. Shetty AK, Mhazo M, Moyo S, von Lieven A, Mateta P, Katzenstein DA, **Maldonado YA**, Hill D, Bassett MT. The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe. International Journal of STD and AIDS. 16:755-9, 2005.
50. Stranix-Chibanda L, Chibanda D, Chingono A, Montgomery E, Wells J, **Maldonado YA**, Chipato T, Shetty AK. Screening for psychological morbidity in HIV-infected and HIV-uninfected pregnant women using community counselors in Zimbabwe. Journal of the International Association of Physicians in AIDS Care. 4:83-8, 2005.
51. Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, Saksena M, Rao CD, Gentsch JR, Parashar U, **Maldonado YA**, Ward RL, Bhan MK. Safety and immunogenicity of two live

attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine. 24:5817-23, 2006.

52. Wells J, Shetty AK, Stranix L, Chipato T, Falkovitz-Halpern MS, Bassett MT, and **Maldonado YA**. Ethnic Neutropenia in Zimbabwean Infants: Implications for monitoring hematologic toxicity due to HIV-1 antiretroviral prophylaxis and treatment in resource poor countries. Journal of Acquired Immune Deficiency Syndrome. 42:460-3, 2006.

53. Wong-Chew RM, Islas-Romero R, Garcia-Garcia MD, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, **Maldonado YA**, Arvin AM, Valdespino-Gomez JL. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine. 24:683-90, 2006.

54. Sarnquist CC, Sullivan B, Cunningham SD, **Maldonado YA**. Evaluation of the relationship between state and national policy and implementation of perinatal HIV prevention interventions. American Journal of Public Health. 97:1041-6, 2006.

55. Kropp RY, Montgomery ET, Sarnquist CD, Ruiz JD, **Maldonado YA**. A Comparison of Perinatal HIV Prevention Opportunities For Hispanic and Non-Hispanic Women in California. AIDS Education and Prevention. 18:430-43, 2006.

56. Berk DR, Falkovitz-Halpern MS, Sullivan B, Ruiz J, **Maldonado YA**. Disease progression among HIV-infected children who receive perinatal zidovudine prophylaxis. Journal of Acquired Immune Deficiency Syndrome. 44:106-11, 2007.

57. Gnanashanmugam D, Fang M, Wong LJ, Biswas S, Hammon R, Rivas-Merelles EE, Santos JI, **Maldonado YA**. Shedding and Household Transmission of Sabin Poliovirus Type 3 after administration of OPV to Mexican infants in a primary OPV vaccination schedule. Journal of Clinical Microbiology. 45:2419- 25, 2007.

58. **Maldonado, YA**. Impact of Fetal and Neonatal Viral (and Parasitic) Infections on Later Development and Disease Outcome. Nestle Nutritional Workshop Series Pediatric Program. 61:225-42, 2008.

59. Rahangdale L, Sarnquist C, **Maldonado YA**, Cohan D. Patient Acceptance of and Satisfaction with Rapid HIV Testing in a Labor and Delivery Setting. Journal of Women's Health. 17: 465-471, 2008.

60. Shetty AK, Marangwanda C, Stranix-Chibanda L, Chandisarewa W, Chirapa E, Mahomva A, Miller A, Simoyi M, **Maldonado YA**. The Feasibility of Preventing Mother-to-Child Transmission of HIV Using Peer Counselors in Zimbabwe. AIDS Research and Therapy. 5:17, 2008.

61. Cohan D, Sarnquist C, Gomez E, Feakins C, **Maldonado YA**, Zetola N. Increased Uptake of HIV Testing With the Integration of Nurse-Initiated HIV Testing Into Routine Prenatal Care. Journal of Acquired Immune Deficiency Syndrome. 49(5):571-573, 2008.

62. Sheikh LA, Sarnquist C, Grieb EM, Sullivan B, **Maldonado YA**. Prenatal Screening for Infectious Diseases: An Analysis of Disparities and Adherence to Policy in California. Maternal and

Child Health Journal. 13(2):260-7, 2009

63. Chibanda D, Mangezi W, Tshimanga M, Woelk G, Rusakaniko P, Stranix-Chibanda L, Midzi S, **Maldonado YA**, Shetty AK. Validation of the Edinburgh Postnatal Depression Scale among women in a high HIV prevalence area in urban Zimbabwe. Archives of Women's Mental Health. 13(3):201-6, 2010.
64. Sarnquist CC, Moix Grieb E, **Maldonado YA**. How Racial and Ethnic Groupings May Mask Disparities: The Importance of Separating Pacific Islanders From Asians in Prenatal Care Data. Maternal and Child Health Journal. 14(4):635-4, 2010.
65. Troy SB, Ferreyra Reyes L, Huang C, Mahmud N, Lee YJ, Canizales Quintero S, Flaster H, Baez Saldaña R, García-García L, **Maldonado YA**. Use of a Novel Real-Time PCR Assay to Detect Oral Polio Vaccine (OPV) Shedding and Reversion in Stool and Sewage Samples after a Mexican National Immunization Day. Journal of Clinical Microbiology. 49:1777-83, 2011.
66. Sarnquist CC, Soni S, Hwang H, Topol BB, Mutima S, **Maldonado YA**. Rural HIV-infected women's access to medical care: ongoing needs in California. AIDS Care. 31:1-5, 2011.
67. Smee N, Shetty AK, Stranix-Chibanda L, Chirneje M, Chipato T, **Maldonado YA**, Portillo C. Factors associated with repeat pregnancy among women in an area of high HIV prevalence in Zimbabwe. Women's Health Issues. 21:222-9, 2011.
68. Elliott CS, Halpern MS, Paik J, **Maldonado YA**, Shortliffe LD. Epidemiologic trends in penile anomalies and hypospadias in the state of California, 1985-2006. Journal of Pediatric Urology. 7:294-8, 2011.
69. Morrison SD, Banushi VH, Sarnquist C, Gashi VH, Osterberg L, **Maldonado YA**, Harxhi A. Barriers to care and current medical and social needs of HIV-positive patients in Albania. Central European Journal of Public Health. 19:91-7, 2011.
70. Giaquinto C, Dominiak-Felden G, Van Damme P, Htar Myint TT, **Maldonado YA**, Spoulou V, Mast TC, Staat MA. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries. Human Vaccines. 7(7), 2011.
71. Copp HL, Halpern MS, **Maldonado YA**, Shortliffe LD. Trends in hospitalization for pediatric pyelonephritis: a population based study of California from 1985 to 2006. Journal of Urology. 186:1028-34, 2011.
72. Morrison S, Sarnquist C, Osterberg L, **Maldonado YA**. Levels of self-reported depression and anxiety amongst HIV-positive patients in Albania. The Croatian Medical Journal. 52:622-8, 2011.
73. Troy SB, Ferreyra-Reyes L, Canizales-Quintero S, Huang CH, Lee Y-J, Báez-Saldaña R, Ferreira-Guerrero E, García-García L, **Maldonado YA**. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a Mexican national immunization day. Journal of Clinical Microbiology. 49(5):1777-83, 2011.

74. Gnanashanmugam D, Troy S, Musingwini G, Huang C, Halpern MS, Stranix-Chibanda L, Shetty AK, Kouiyavskaia D, Nathoo K, Chumakov K, **Maldonado YA**. Immunologic Response to Oral Polio Vaccine in HIV-Infected and Uninfected Zimbabwean Children. Pediatric Infectious Disease Journal. 31:176-80, 2012.
75. Sturt AS, **Maldonado YA**. Timing of Antiretroviral Therapy Initiation and its Impact on Progression to Moderate and Severe Disease in Perinatal HIV-1 Infection. The Pediatric Infectious Disease Journal. 31:53-60, 2012.
76. Nelson K, Janssen JM, Troy SB, **Maldonado YA**. Intradermal fractional dose inactivated polio vaccine: A review of the literature. Vaccine. 30:121-5, 2012.
77. Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, Musoke P, Stranix-Chibanda L, Chetty V, Fawzi W, Nakabiito C, Msweli L, Kisenge R, Guay L, Mwatha A, Lynn DJ, Eshleman SH, Richardson P, George K, Andrew P, Mofenson LM, Zwierski S, **Maldonado YA**; for the HPTN 046 protocol team. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 379(9812):221-8, 2012.
78. Troy SB, Rowhani-Rahbar A, Dyner L, Musingwini G, Shetty AK, Woelk G, Stranix-Chibanda L, Nathoo K, **Maldonado YA**. Hematologic and immunologic parameters in Zimbabwean infants: a case for using local reference intervals to monitor toxicities in clinical trials. Journal of Tropical Pediatrics. 58:59- 62, 2012.
79. Troy SB, Ferreyra-Reyes L, Canizales-Quintero S, Huang CH, Lee Y-J, Baez-Saldana R, Ferreira- Guerrero E, Garcia-Garcia L, **Maldonado YA**. Real-time Polymerase Chain Reaction Analysis of Sewage Samples to Determine Oral Polio Vaccine Circulation Duration and Mutation After Mexican National Immunization Weeks. Journal of the Pediatric Infectious Diseases Society. 1:223-9, 2012.
80. **Maldonado YA**. Measles vaccine, HIV infection, and antiretroviral therapy – a window of opportunity. Journal of Infectious Diseases. 206:466-8, 2012.
81. Sturt AS, Anglemeyer A, Berk DR, **Maldonado YA**. Temporal Trends in Mucocutaneous Findings Among Human Immunodeficiency Virus 1-Infected Children in a Population-Based Cohort. Pediatric Dermatology. Nov 7, 2012. [Epub ahead of print].
82. Sarnquist C, Sawyer M, Calvin K, Mason W, Blumberg D, Luther J, **Maldonado YA**. Communicating about vaccines and vaccine safety: What are medical residents learning and what do they want to learn? Journal of Public Health Management & Practice. 19:40-46, 2013.
83. Gutierrez K, Halpern MS, Sarnquist C, Soni S, Arroyo AC, **Maldonado YA**. Staphylococcal infections in children, California, USA, 1985-2009. Emerging Infectious Diseases. 19:10-20, 2013.
84. Troy SB, Musingwini G, Halpern MS, Huang CH, Stranix-Chibanda L, Kouiyavskaia D, Shetty AK, Chumakov K, Nathoo K, **Maldonado YA**. Vaccine Poliovirus Shedding and Immune Response to Oral Polio Vaccine in HIV-Infected and Uninfected Zimbabwean Infants. Journal of Infectious Diseases. May 14, 2013. [Epub ahead of print]

85. Sarnquist CC, Rahangdale L, **Maldonado YA**. Reproductive Health and Family Planning Needs among HIV-Infected Women in Sub-Saharan Africa. Current HIV Research. 11(2):160-8, 2013.
86. Shetty AK, **Maldonado YA**. Antiretroviral Drugs to Prevent Mother-to-Child Transmission of HIV during Breastfeeding. Current HIV Research. 11(2):102-25, 2013.
88. Gans HA, **Maldonado YA**. Loss of Passively-Acquired Maternal Antibodies in Highly Vaccinated Populations: An Emerging Need to Define the Ontogeny of Infant Immune Responses. Journal of Infectious Diseases. 208(1):1-3, 2013.
89. Watts HD, Brown ER, **Maldonado YA**, Herron C, Chipato T, Reddy L, Moodley D, Nakabiito C, Manji K, Fawzi W, George K, Richardson P, Zwierski S, Coovadia C, Fowler MG, for the HPTN 046 protocol team. HIV Disease Progression in the First Year after Delivery among African Women followed in the HPTN 046 Clinical Trial. Journal of Acquired Immune Deficiency Syndromes.64(3):299-306, 2013.
90. Sturt AS, Anglemyer AT, DuBray K, **Maldonado YA**. Temporal trends in otolaryngologic findings among HIV-1-infected children in a population-based cohort. Pediatric Infectious Disease Journal. 33(3):e76-80, 2014.
91. Sarnquist CC, Moyo P, Stranix-Chibanda L, Chipato T, Kang JL, **Maldonado YA**. Integrating family planning and prevention of mother to child HIV transmission in Zimbabwe. Contraception. 89(3):209-14, 2014.
92. Troy SB, Ferreyra-Reyes L, Huang C, Sarnquist C, Canizales-Quintero S, Nelson C, Báez-Saldaña R, Holubar M, Ferreira-Guerrero E, García-García L, **Maldonado YA**. Community circulation patterns of oral polio vaccine serotypes 1, 2, and 3 after Mexican national immunization weeks. Journal of Infectious Diseases. 209(11):1693-9, 2014
93. Morrison SD, Rashidi V, Sarnquist C, Banushi VH, Hole MK, Barbhaiya NJ, Gashi VH, Osterberg L, **Maldonado YA**, Harxhi A. Antiretroviral therapy adherence and predictors to adherence in Albania: a cross-sectional study. Journal of Infection in Developing Countries. 8(7):853-862, 2014.
94. Troy SB, Kouliavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, **Maldonado YA**. Comparison of the immunogenicity of various inactivated polio vaccine booster doses by intradermal versus intramuscular routes in HIV-infected adults. Journal of Infectious Diseases. 211(12):1969-76, 2015.
95. Guo J, Wagers SB, Srinivas N, Holubar M, **Maldonado YA**. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication. Vaccine. 33(10):1235-42, 2015.
96. Contopoulos-Ioannidis DG, Halpern MS, **Maldonado YA**. Trends in Hospitalizations for Intussusception in California in Relationship to the Introduction of New Rotavirus Vaccines, 1985-2010. Pediatr Infect Dis J. 34(7):712-7, 2015.
97. Contopoulos-Ioannidis D, Talucod J, **Maldonado YA**, Montoya JG. Seasonal variation of acute toxoplasmic lymphadenopathy in the United States. Epidemiol Infect. 143:1893-7, 2015.

98. Contopoulos-Ioannidis D, Wheeler KM, Ramirez R, Press C, Mui E, Zhou Y, Van Tubbergen C, Prasad S, **Maldonado Y**, Withers S, Boyer KM, Noble AG, Rabiah P, Swisher CN, Heydemann P, Wroblewski K, Karrison T, Grigg ME, Montoya JG, McLeod R. Clustering of *Toxoplasma gondii* Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 61(12):1815-24, 2015.
99. Contopoulos-Ioannidis D, Tseretopoulou X, Ancker M, Walterspiel JN, Panagiotou OA, **Maldonado Y**, Ioannidis J. Comparative Rates of Harms in Randomized Trials from More-Developed Versus Less-Developed Countries May be Different. J Clin Epidemiol. 8:10-21, 2016.
100. McNeil CJ, Kong CS, Anglemyer A, Levy V, **Maldonado Y**. Results of the Women's Self-Performed Anal Pap Trial in Human Immunodeficiency Virus-Infected Women. Sex Trans Dis. 2016 43:433-5.
101. Aftandilian C, Weinberg K, Willert J, Kharbanda S, Porteus M, **Maldonado Y**, Agarwal R. Invasive Fungal Disease in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant. J Pediatr Hematol Oncol. 38:574-580, 2016.
102. Holubar M, Troy SB, Nathoo K, Stranix-Chibanda L, Musingwini G, Srinivas N, Huang C, Junn A, Halpern MS, **Maldonado YA**. Shedding of Oral Poliovirus Vaccine (OPV) by HIV-Infected and -Uninfected Mothers of OPV-Vaccinated Zimbabwean Infants. J Pediatric Infect Dis Soc. 2017;6(1):105-108, 2017.
103. Sarnquist C, Sinclair J, Omondi Mboya B, Langat N, Paiva L, Halpern-Felsher B, Golden NH, **Maldonado YA**, Baiocchi MT. Evidence That Classroom-Based Behavioral Interventions Reduce Pregnancy-Related School Dropout Among Nairobi Adolescents. Health Educ Behav. 44(2):297-303, 2017.
104. Holubar M, Stavroulakis MC, **Maldonado Y**, Ioannidis JP, Contopoulos-Ioannidis D. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. PLoS One. 12(3):e0172414, 2017.
105. Sahoo MK, Holubar M, Huang C, Mohamed-Hadley A, Liu Y, Waggoner JJ, Troy SB, Garcia-Garcia L, Ferreyra-Reyes L, **Maldonado Y**, Pinsky BA. Detection of Emerging Vaccine-Related Polioviruses by Deep Sequencing. J Clin Microbiol. (7):2162-2171, 2017
106. Begeman IJ, Lykins J, Zhou Y, Lai BS, Levigne P, El Bissati K, Boyer K, Withers S, Clouser F, Noble AG, Rabiah P, Swisher CN, Heydemann PT, Contopoulos-Ioannidis DG, Montoya JG, **Maldonado Y**, Ramirez R, Press C, Stillwaggon E, Peyron F, McLeod R. Point-of-care testing for *Toxoplasma gondii* IgG/IgM using *Toxoplasma* ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 11(6):e0005670, 2017.
107. Fassiotto M, **Maldonado Y**, Hopkins J. A long-term follow-up of a physician leadership program. J Health Organ and Manag. 32(1):56-68, 2017.
108. Ferreyra-Reyes L, Cruz-Hervert LP, Troy SB, Huang C, Sarnquist C, Delgado-Sánchez G, Canizales-Quintero S, Holubar M, Ferreira-Guerrero E, Montero-Campos R, Rodríguez-Álvarez M, Mongua-Rodríguez N, **Maldonado Y**, García-García L. Assessing the individual risk of fecal poliovirus shedding among vaccinated and non-vaccinated subjects following national health weeks in Mexico. PLoS One. 212(10):e0185594, 2017.
109. Rogo-Gupta LJ, Haunschild C, Altamirano J, **Maldonado YA**, Fassiotto M. Physician Gender Is Associated with Press Ganey Patient Satisfaction Scores in Outpatient Gynecology. Womens Health Issues. 28(3):281-285, 2018.

110. O'Leary ST, **Maldonado YA**. Safety of Multiple Antigen Exposure in the Childhood Immunization Schedule. JAMA. 319(9):870-871, 2018
111. Akinboyo IC, Sick-Samuels AC, Singeltary E, Fackler J, Ascenzi J, Carroll KC, **Maldonado Y**, Brooks RB, Benowitz I, Wilson LE, LiPuma JJ, Milstone AM. Multistate Outbreak of an Emerging *Burkholderia cepacia* Complex Strain Associated With Contaminated Oral Liquid Docusate Sodium. Infect Control Hosp Epidemiol. 39(2):237-239, 2018.
112. Anglemeyer A, Sturt A, **Maldonado Y**. The Effect of Combination Antiretroviral Therapy Use Among HIV Positive Children on the Hazard of AIDS Using Calendar Year as an Instrumental Variable. Curr HIV Res. 16(2):151-157, 2018.
113. Fassiotto M, Li J, **Maldonado Y**, Kothary N. Female Surgeons as Counter Stereotype: The Impact of Gender Perceptions on Trainee Evaluations of Physician Faculty. J Surg Educ. Feb 2. pii: S1931-7204(17)30708-0, 2018.
114. O'Leary ST, Kimberlin DW, **Maldonado YA**. Update From the Advisory Committee on Immunization Practices. J Pediatric Infect Dis Soc. 7(2):93-99, 2018.
115. Lykins J, Li X, Levigne P, Zhou Y, El Bissati K, Clouser F, Wallon M, Morel F, Leahy K, El Mansouri B, Siddiqui M, Leong N, Michalowski M, Irwin E, Goodall P, Ismail M, Christmas M, Adlaoui EB, Rhajaoui M, Barkat A, Cong H, Begeman IJ, Lai BS, Contopoulos-Ioannidis DG, Montoya JG, **Maldonado Y**, Ramirez R, Press C, Peyron F, McLeod R. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for anti-*Toxoplasma* antibodies. PLoS Negl Trop Dis. 12(8):e0006536, 2018.
116. Tedesco D, Farid-Kapadia M, Offringa M, Bhutta ZA, **Maldonado Y**, Ioannidis JPA, Contopoulos-Ioannidis DG. Comparative evidence on harms in pediatric randomized clinical trials from less developed versus more developed countries is limited. J Clin Epidemiol. 2018:95:63-72.
117. Gomez CA, Budvytyte LN, Press C, Zhou L, McLeod R, **Maldonado Y**, Montoya JG, Contopoulos-Ioannidis DG. Evaluation of Three Point-of-Care Tests for Detection of *Toxoplasma* Immunoglobulin IgG and IgM in the United States: Proof of Concept and Challenges. Open Forum Infect Dis. 2018;5:ofy215.
118. Sarnquist C, Holubar M, Garcia-Garcia L, Ferreyra Reyes L, Montero-Campos R, Cruz-Hervert LP, Altamirano J, Purington N, Boyle S, Modlin J, Ferreira E, Delgado G, Canizales-Quintero S, Desai M, **Maldonado Y**. Protocol Paper: Oral poliovirus transmissibility in communities after cessation of routine oral poliovirus vaccine immunization. Clin Infect Dis. 2018 Oct 30;67(suppl_1):S115-120.
119. Van Hoorebeke C, Huang C, Holubar M, Leary S, Altamirano J, Sommer M, Halpern M, **Maldonado Y**. Use of a high-throughput, multiplex rt-QPCR assay for detection of Sabin Oral Polio Vaccine in Fecal Samples. Clin Infect Dis. 2018 Oct 30;67(suppl_1):S121-126.
120. Altamirano J, Purington N, Behl R, Sarnquist C, Holubar M, Garcia-Garcia L, Ferreyra Reyes L, Montero-Campos R, Cruz-Hervert LP, Boyle S, Modlin J, Van Hoorebeke C, Leary S, Huang C, Sommer M, Ferreira E, Delgado G, Canizales-Quintero S, Diaz-Ortega J, Desai M, **Maldonado Y**. Characterization of Household and Community Shedding and Transmission of Oral Poliovirus Vaccine in Mexican Communities with Varying Vaccination Coverage. Clin Infect Dis. 2018 Oct 30;67(suppl_1):S4-17.

121. Jarvis C, Altamirano J, Sarnquist C, Edmunds J, **Maldonado Y**. Spatial Analyses of Oral Poliovirus Vaccine Transmission in an IPV-vaccinated Community. *Clin Infect Dis*. 2018 Oct 30;67(suppl_1):S18-25.
122. Altamirano J, Leary S, Van Hoorebeke C, Sarnquist C, Behl R, Garcia-Garcia L, Ferreyra Reyes L, Huang C, Sommer M, **Maldonado Y**. Validation of a high-throughput, multiplex rt-QPCR assay for detection of Sabin Oral Polio Vaccine in Environmental Samples. *Clin Infect Dis*. 2018 Oct 30;67(suppl_1):S98-102.
123. Halpern M, Altamirano J, **Maldonado Y**. Reverse Proportion in Samples with Evidence of Oral Polio Vaccine Shedding: Comparing HIV-Infected and –Uninfected Vaccinated Infants. *Clin Infect Dis*. 2018 Oct 30;67(suppl_1):S78-84.
124. Altamirano J, Sarnquist C, Behl R, Garcia-Garcia L, Ferreyra Reyes L, Leary S, **Maldonado Y**. OPV Vaccination and Shedding Patterns in Mexican and US Children. *Clin Infect Dis*. 2018 Oct 30;67(suppl_1):S85-89.
125. Fu R, Altamirano J, Sarnquist C, **Maldonado Y**, Andrews J. Assessing the Risk of Vaccine-derived Outbreaks Following Re-introduction of Oral Polio Vaccine in Post-Cessation Settings. *Clin Infect Dis*. 2018 Oct 30;67(suppl_1):S26-34.
126. Marcelin JR, Siraj DS, Victor R, Kotadia S, Maldonado YA. The Impact of Unconscious Bias in Healthcare: How to Recognize and Mitigate It. *J Infect Dis*. 220(Supplement_2):S62-S73, 2019.
126. Rostami A, Riahi SM, Contopoulos-Ioannidis DG, Gamble HR, Fakhri Y, Shiadeh MN, Foroutan M, Behniafar H, Taghipour A, Maldonado YA, Mokdad AH, Gasser RB. Acute Toxoplasma infection in pregnant women worldwide: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 14;13(10):e0007807, 2019
127. Krasnow MR, Maldonado YA, Contopoulos-Ioannidis DG. Congenital microcephaly hospitalizations in California infants: 1999-2013. *Birth Defects Res*. 111(19):1535-1542, 2019.
128. Holubar M, Sahoo MK, Huang C, Mohamed-Hadley A, Liu Y, Waggoner JJ, Troy SB, García-García L, Ferreyra-Reyes L, **Maldonado Y**, Pinsky BA. Deep sequencing prompts the modification of a real-time RT-PCR for the serotype-specific detection of polioviruses. *J Virol Methods*. 2019;264:38-43.
129. Perez MG, Fassiotto M, Altamirano J, Hwang GL, **Maldonado Y**, Josephs S, Sze DY, Kothary N. Untapped Resources: Attaining Equitable Representation for Women in IR. *J Vasc Interv Radiol*. 2019 Apr;30(4):579-583.
130. Seddik TB, Tian L, Nespor C, Kerner J, **Maldonado Y**, Gans H. Risk Factors of Ambulatory Central Line-Associated Bloodstream Infection in Pediatric Short Bowel Syndrome. *J Parenter Enteral Nutr*. 2019 Jun 9. [Epub ahead of print]
131. Marcelin JR, Siraj DS, Victor R, Kotadia S, **Maldonado YA**. The Impact of Unconscious Bias in Healthcare: How to Recognize and Mitigate It. *J Infect Dis*. 2019;220(Supplement_2):S62-S73.
132. Ghatan CE, Altamirano J, Fassiotto M, Perez MG, **Maldonado Y**, Josephs S, Sze DY, Kothary N. Achieving Speaker Gender Equity at the SIR Annual Scientific Meeting: The Effect of Female Session Coordinators. *J Vasc Interv Radiol*. 2019 Oct 3.

133. Onyango-Makumbi C, Owora AH, Mwiru RS, Mwatha A, Young AM, Moodley D, Coovadia HM, Stranix-Chibanda L, Manji K, **Maldonado Y**, Richardson P, Andrew P, George K, Fawzi W, Fowler MG. Extended prophylaxis with nevirapine does not affect growth in HIV-exposed infants. *J Acquir Immune Defic Syndr*. 2019 Sep 13.
134. Nyathi S, Karpel HC, Sainani KL, **Maldonado Y**, Hotez PJ, Bendavid E, Lo NC. The 2016 California policy to eliminate nonmedical vaccine exemptions and changes in vaccine coverage: An empirical policy analysis. *PLoS Med*. 2019 Dec 23;16(12):e1002994.
135. Graham LA, **Maldonado YA**, Tompkins LS, Wald SH, Chawla A, Hawn MT. Asymptomatic SARS-CoV-2 Transmission From Community Contacts in Healthcare Workers . *Ann Surg*. 2;10, 2020 (ePub ahead of print).
136. Altamirano J, Govindarajan P, Blomkalns AL, Kushner LE, Stevens BA, Pinsky BA, **Maldonado Y**. Assessment of Sensitivity and Specificity of Patient-Collected Lower Nasal Specimens for Sudden Acute Respiratory Syndrome Coronavirus 2 Testing. *JAMA Netw Open*.;3(6):e2012005, 2020.
137. Garcia LC, Shanafelt TD, West CP, Sinsky CA, Trockel MT, Nedelec L, **Maldonado YA**, Tutty M, Dyrbye LN, Fassiottto M Burnout, Depression, Career Satisfaction, and Work-Life Integration by Physician Race/Ethnicity. *JAMA Netw Open*. 2020 Aug 3;3(8):e2012762.
138. Tusty M, Flores B, Victor R, Fassiottto M, **Maldonado Y**, Howard J, Valdez TA. The Long "Race" to Diversity in Otolaryngology. *Otolaryngol Head Neck Surg*. 2020 Aug 25:194599820951132.
139. Fassiottto M, Flores B, Victor R, Altamirano J, Garcia LC, Kotadia S, **Maldonado Y**. Rank Equity Index: Measuring Parity in the Advancement of Underrepresented Populations in Academic Medicine *Acad Med*. 2020 Sep 1. doi: 10.1097/ACM.0000000000003720.
140. Tan SK, Granados AC, Bouquet J, Hoy-Schulz YE, Green L, Federman S, Stryke D, Haggerty TD, Ley C, Yeh MT, Jannat K, **Maldonado YA**, Andino R, Parsonnet J, Chiu CY. Metagenomic sequencing of stool samples in Bangladeshi infants: virome association with poliovirus shedding after oral poliovirus vaccination *Sci Rep*. 2020 Sep 21;10(1):15392. doi: 10.1038/s41598-020-71791-4.

Peer Reviewed Policy and Guidelines Publications (Maldonado as member of the Committees)

1. Bernstein HH, Starke JR; American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement--recommendation for mandatory influenza immunization of all health care personnel. *Pediatrics*. 126:809-15, 2010.
2. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement—recommendations for prevention and control of influenza in children, 2010-2011. *Pediatrics*. 126:816-26, 2010.
3. American Academy of Pediatrics. Committee on Infectious Diseases. Rabies-prevention policy update: new reduced-dose schedule. *Pediatrics*. 127:785-7, 2011.
4. American Academy of Pediatrics. Committee on Infectious Diseases; American Academy of Pediatrics. Policy statement--recommended childhood and adolescent immunization schedules--United States, 2011. *Pediatrics*. 127:387-8, 2011.
5. American Academy of Pediatrics. Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. *Pediatrics*. 128:1213-8, 2011.

6. Lessin HR, Edwards KM; Committee On Practice And Ambulatory Medicine; Committee On Infectious Diseases. Immunizing parents and other close family contacts in the pediatric office setting. Pediatrics. 129(1):e247-53, 2012.
7. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedules--United States, 2012. Pediatrics. 129(2):385-6, 2012.
8. Committee on Infectious Diseases. HPV vaccine recommendations. Pediatrics. 129(3):602-5, 2012.
9. Polin RA, Denson S, Brady MT; Committee on Fetus and Newborn; Committee on Infectious Diseases. Epidemiology and diagnosis of health care-associated infections in the NICU. Pediatrics. 129(4):e1104-9, 2012.
10. Polin RA, Denson S, Brady MT; Committee on Fetus and Newborn; Committee on Infectious Diseases. Strategies for prevention of health care-associated infections in the NICU. Pediatrics. 129(4):e1085-93, 2012.
11. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics. 130:780-92, 2012.
12. Schutze GE, Willoughby RE; Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics. 131(1):196-200, 2013.
13. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule-United States, 2013. Pediatrics. 131(2):397-8, 2013.
14. Kimberlin DW, Baley J; Committee on Infectious Diseases; Committee on Fetus and Newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics. 131(2):383-6, 2013.
15. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics. 132(4):e1089-104, 2013.
16. Committee on Infectious Diseases; Committee on Nutrition; American Academy of Pediatrics. Consumption of raw or unpasteurized milk and milk products by pregnant women and children. Pediatrics. 133(1):175-9, 2014.
17. Committee on Infectious Diseases, American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule--United States, 2014. Pediatrics. 133(2):357-63, 2014.
18. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 134(2):e620-38, 2014.
19. American Academy of Pediatrics Committee on Infectious Diseases. Updated Recommendations on the use of meningococcal vaccines. Pediatrics. 134(2):400-3, 2014.
20. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics

Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. 134(2):415-20, 2014.

21. Committee On Infectious Diseases; American Academy Pediatrics. Recommendations for prevention and control of influenza in children, 2014-2015. *Pediatrics*. 134(5):e1503-19, 2014.

22. Committee On Infectious Diseases. Immunization for *Streptococcus pneumoniae* infections in high risk children. *Pediatrics*. 134(6):1230-3, 2014.

23. Starke JR; Committee On Infectious Diseases. Interferon- γ release assays for diagnosis of tuberculosis infection and disease in children. *Pediatrics*. 134(6):e1763-73, 2014.

24. Meissner HC, Brady MT, Byington CL, Kimberlin DW, Lieberthal AS, Maldonado YA, Ralston SL, Winterstein A. Authors' responses in response to the letter from Ambrose. *Pediatrics*. 134(6):e1782-3, 2014.

25. Orenstein WA; Committee on Infectious Diseases. Eradicating Polio: How the World's Pediatricians Can Help Stop This Crippling Illness Forever. *Pediatrics*. 135(1):196-202, 2015.

26. Committee on Infectious Diseases; American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule-United States, 2015. *Pediatrics*. 135(2):396-7, 2015.

27. Devore CD, Schutze GE; Council on School Health and Committee on Infectious Diseases, American Academy of Pediatrics. Head lice. *Pediatrics*. 135(5):e1355-65, 2015.

28. National Vaccine Advisory Committee. The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014. *Public Health Rep*. Jan-Feb;130(1):10-42, 2015.

29. Committee on Infectious Diseases. Influenza Immunization for All Health Care Personnel: Keep It Mandatory. *Pediatrics*. 136(4):809-18., 2015.

30. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for Prevention and Control of Influenza in Children, 2015-2016. *Pediatrics*. 2015 Oct;136(4):792-808, 2015.

31. Paulson JA, Zaoutis TE; Council on Environmental Health; Committee on Infectious Diseases. Nontherapeutic Use of Antimicrobial Agents in Animal Agriculture: Implications for Pediatrics. *Pediatrics*. 136(6):e1670-7, 2015.

32. COMMITTEE ON INFECTIOUS DISEASES; American Academy of Pediatrics. Recommended Childhood and Adolescent Immunization Schedule--United States, 2016. *Pediatrics*. 137(3):e20154531, 2016.

33. Davies HD; COMMITTEE ON INFECTIOUS DISEASES. Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children. *Pediatrics*. 138(2). pii: e20161209, 2016.

34. Davies HD, Byington CL; COMMITTEE ON INFECTIOUS DISEASES. Parental Presence During Treatment of Ebola or Other Highly Consequential Infection. *Pediatrics*. 138(3). pii: e20161891, 2016.

35. COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Serogroup

Meningococcal Vaccine for Persons 10 Years and Older. Pediatrics. 2016 Sep;138(3). pii: e20161890.

36. COMMITTEE ON PRACTICE AND AMBULATORY MEDICINE; COMMITTEE ON INFECTIOUS DISEASES; COMMITTEE ON STATE GOVERNMENT AFFAIRS; COUNCIL ON SCHOOL HEALTH; SECTION ON ADMINISTRATION AND PRACTICE MANAGEMENT. Medical Versus Nonmedical Immunization Exemptions for Child Care and School Attendance. Pediatrics. 2016 Sep;138(3). pii: e20162145.

37. Edwards KM, Hackell JM; COMMITTEE ON INFECTIOUS DISEASES, THE COMMITTEE ON PRACTICE AND AMBULATORY MEDICINE. Countering Vaccine Hesitancy. Pediatrics. 2016 Sep;138(3). pii: e20162146.

38. COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control Of Influenza in Children, 2016-2017. Pediatrics. 2016 Sep 6. pii: e20162527. [Epub ahead of print]

39. Jackson MA, Schutze GE; COMMITTEE ON INFECTIOUS DISEASES. The use of systemic and topical fluoroquinolones. Pediatrics. 2016 Nov;138(5). pii: e20162706.

40. **Maldonado YA**, Read JS; COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, Treatment and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics. 2017 Feb;139(2). pii: e20163860. doi: 10.1542/peds.2016-3860.

41. Bernstein HH, Bocchini JA Jr; COMMITTEE ON INFECTIOUS DISEASES. Practical approaches to optimize adolescent immunization. Pediatrics. 2017 Mar;139(3). pii: e20164187.

42. Bernstein HH, Bocchini JA Jr; COMMITTEE ON INFECTIOUS DISEASES. The need to optimize adolescent immunization. Pediatrics. 2017 Mar;139(3). pii: e20164186. doi: 10.1542/peds.2016-4186.

43. O'Leary ST, **Maldonado YA**. Adverse Events Following Immunization: Will It Happen Again? Pediatrics. 2017 Sep;140(3). pii: e20171760.

44. O'Leary ST, Kimberlin DW, Maldonado, YA. Update from the Advisory Committee on Immunization J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):215-218.

45. Davies HD, Jackson MA, Rice SG; COMMITTEE ON INFECTIOUS DISEASES; COUNCIL ON SPORTS MEDICINE AND FITNESS. [Infectious Diseases Associated With Organized Sports and Outbreak Control](#). Pediatrics. 2017 Oct;140(4). pii: e20172477

46. Rathore MH, Jackson MA; COMMITTEE ON INFECTIOUS DISEASES. [Infection Prevention and Control in Pediatric Ambulatory Settings](#). Pediatrics. 2017 Nov;140(5). pii: e20172857.

47. COMMITTEE ON INFECTIOUS DISEASES. [Recommendations for Prevention and Control of Influenza in Children, 2018-2019](#). Pediatrics. 2018 Sep 3. pii: e20182367. doi: 10.1542/peds.2018-2367. [Epub ahead of print].

48. COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2018-2019. Pediatrics. 2018 Oct;142(4). pii: e20182367. doi: 10.1542/peds.2018-2367. Epub 2018 Sep 3.

49. Puopolo KM, Benitz WE, Zaoutis TE; COMMITTEE ON FETUS AND NEWBORN; COMMITTEE ON INFECTIOUS DISEASES. Management of Neonates Born at ≥ 35 0/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis. *Pediatrics*. 2018;142. pii: e20182894. doi: 10.1542/peds.2018-2894.
50. Puopolo KM, Benitz WE, Zaoutis TE; COMMITTEE ON FETUS AND NEWBORN; COMMITTEE ON INFECTIOUS DISEASES. Management of Neonates Born at ≤ 34 6/7 Weeks' Gestation With Suspected or Proven Early-Onset Bacterial Sepsis. *Pediatrics*. 2018;142.
51. COMMITTEE ON INFECTIOUS DISEASES. Recommended Childhood and Adolescent Immunization Schedules: United States, 2019. *Pediatrics*. 2019 Mar;143(3).
52. Puopolo KM, Lynfield R, Cummings JJ; COMMITTEE ON FETUS AND NEWBORN; COMMITTEE ON INFECTIOUS DISEASES. Management of Infants at Risk for Group B Streptococcal Disease. *Pediatrics*. 2019 Jul 8. pii: e20191881.
53. O'Leary ST, Maldonado YA, Kimberlin DW. Update From the Advisory Committee on Immunization Practices. *J Pediatric Infect Dis Soc*. 2019 Aug 1 [Epub ahead of print]
54. COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2019-2020. *Pediatrics*. 2019 Oct;144(4).
55. O'Leary ST, Maldonado YA, Kimberlin DW. Update From the Advisory Committee on Immunization Practices. *J Pediatric Infect Dis Soc*. 2019 Oct 7. [Epub ahead of print]
56. COMMITTEE ON INFECTIOUS DISEASES. Recommended Childhood and Adolescent Immunization Schedule: United States, 2020. *Pediatrics*. 2020 Mar;145(3):e20193995. doi: 10.1542/peds.2019-3995. Epub 2020 Feb 4. PMID: 32019815
57. O'Leary ST, Maldonado YA, Kimberlin DW. Update from the Advisory Committee on Immunization Practices. *J Pediatric Infect Dis Soc*. 2020 Feb 28;9(1):3-5. doi: 10.1093/jpids/piaa008. PMID: 32016424
58. Chung S, Baum CR, Nyquist AC; Disaster Preparedness Advisory Council, Council on Environmental Health, Committee on Infectious Diseases. Chemical-Biological Terrorism and Its Impact on Children. *Pediatrics*. 2020 Feb;145(2):e20193749. doi: 10.1542/peds.2019-3749. PMID: 31988169
59. O'Leary ST, Maldonado YA. Vaccination Policies and Disease Incidence Across the Pond: Implications for the United States. *Pediatrics*. 2020 Feb;145(2):e20192436. doi: 10.1542/peds.2019-2436. Epub 2020 Jan 13. PMID: 31932360
60. Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2020-2021. 2020 Oct;146(4):e2020024588. doi: 10.1542/peds.2020-024588. Epub 2020 Sep 8.

A.3 Books

1. Associate Editor, Remington JS, Klein JO (Eds.) *Infectious Diseases of the Fetus and Newborn Infant*, W.B. Saunders Company, Philadelphia, 7th edition, 2010.
2. Co-Editor, Report of the Committee on Infectious Diseases ("Red Book"), American Academy of Pediatrics, Evanston, IL, 29th edition, 2013.

3. Associate Editor, Remington JS, Klein JO (Eds.) *Infectious Diseases of the Fetus and Newborn Infant*, W.B. Saunders Company, Philadelphia, 8th edition, 2015.
4. Co-Editor, Report of the Committee on Infectious Diseases (“Red Book”), American Academy of Pediatrics, Evanston, IL, 30th edition, 2015.
5. Co-Editor, Report of the Committee on Infectious Diseases (“Red Book”), American Academy of Pediatrics, Evanston, IL, 31st edition, 2018.
6. Co-Editor, Report of the Committee on Infectious Diseases (“Red Book”), American Academy of Pediatrics, Evanston, IL, 32nd edition, 2021 (pending).
7. Senior Associate Editor, Remington JS, Klein JO (Eds.) *Infectious Diseases of the Fetus and Newborn Infant*, W.B. Saunders Company, Philadelphia, 9th edition, 2021 (pending).

A.4 Book chapters

1. **Maldonado YA**: *Infectious Diseases*. Cole CH (Ed.) The Harriet Lane Handbook, 10th Edition, Year Book Medical Publishers, Inc., Chicago, 1983.
2. **Maldonado YA** and Yolken RH: *Rotaviruses*. Farthing MJG, Keusch GT (Eds.) Enteric Infection: Mechanisms, Manifestations and Management, Chapman & Hall LTD, London, 1988.
3. **Maldonado YA** and Yolken RH: Rotavirus. Farthing MJG (Guest Ed.) Balliere's Clinical Gastroenterology, International Practice and Research, Bailliere Tindall, London, 1990.
4. **Maldonado YA** and Petru A: *Diagnosis of Pediatric HIV Disease*. Cohen PT, Sande MA, Volberding PA (Eds.) The AIDS Knowledge Base, Little, Brown and Company, Boston, 2nd edition, 1990.
6. **Maldonado YA**, Arvin AM, Ruskin J, and Yeager AS: *Protozoan and Helminth Infections (Including Pneumocystis carinii)*. Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 4th edition, 1996.
7. Arvin AM, **Maldonado YA**: *Other Viral Infections*. Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 4th edition, 1996.
8. **Maldonado YA**: *Measles*. Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 15th edition, 1996.
9. **Maldonado YA**: *Mumps*. Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 15th edition, 1996.
10. **Maldonado YA**: *Rubella*. Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 15th edition, 1996.

11. **Maldonado YA:** *Epidemiology of HIV infection in children and adolescents.* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 1st edition, 1997.
12. **Maldonado YA:** *Prevention of HIV infection.* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 1st edition, 1997.
13. **Maldonado YA:** *Rubella virus.* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 1st edition, 1997.
14. **Maldonado YA:** *Rubeola virus (Measles and Subacute Sclerosing Panencephalitis).* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 1st edition, 1997.
15. **Maldonado YA:** *Perinatal HIV Infection.* Sunshine P and Stevenson D (Eds.) Fetal and Neonatal Brain Injury: Mechanisms, Management, and the Risks of Practice, Oxford University Press, Oxford, 2nd edition, 1997.
16. **Maldonado YA,** Arvin AM, Ruskin J, and Yeager AS: *Protozoan and Helminth Infections (Including Pneumocystic carinii).* Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 5th edition, 2001.
17. Arvin AM, **Maldonado YA:** *Other Viral Infections.* Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 5th edition, 2001.
18. **Maldonado YA:** *Measles.* Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 16th edition, 1999.
19. **Maldonado YA:** *Mumps.* Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 16th edition, 1999.
20. **Maldonado YA:** *Rubella.* Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 16th edition, 1999.
21. **Maldonado YA:** *Measles, Rubella, Mumps.* Wilfert C (Ed.) Atlas of Infectious Diseases, volume 11, Pediatric Infectious Diseases, Current Medicine, Inc., Philadelphia, 1st edition, 1999.
22. **Maldonado YA,** Shetty, AK: *Epidemiology of HIV infection in children and adolescents.* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 2nd edition, 2003.
23. **Maldonado YA:** *Polioviruses.* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 2nd edition, 2003.
24. **Maldonado YA:** *Rubella virus.* Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and

Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 2nd edition, 2003.

25. **Maldonado YA:** *Rubeola virus (Measles and Subacute Sclerosing Panencephalitis)*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 2nd edition, 2003.
26. **Maldonado YA, Enright AM:** *Perinatal HIV Infection*. Sunshine P and Stevenson D (Eds.) Fetal and Neonatal Brain Injury: Mechanisms, Management, and the Risks of Practice, Oxford University Press, Oxford, 3rd edition, 2003.
27. **Maldonado YA:** *Measles*. Rakel RE and Bope ET (Eds) Conn's Current Therapy 2003, WB Saunders, Philadelphia, PA, 2003.
28. **Maldonado YA:** *Measles (Rubeola)*. Rakel RE and Bope ET (Eds) Conn's Current Therapy 2004, WB Saunders, Philadelphia, PA, 2004.
29. **Maldonado YA:** *Measles*. Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 17th edition, 2004.
30. **Maldonado YA:** *Mumps*. Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 17th edition, 2004.
31. **Maldonado YA:** *Rubella*. Behrman RE, Kliegman RM, Arvin AM (Eds.) Nelson Textbook of Pediatrics, W.B. Saunders Company, Philadelphia, 17th edition, 2004.
32. **Maldonado YA:** *Acquired Immunodeficiency Syndrome in the Infant..* Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 6th edition, 2006.
33. **Maldonado YA:** *Less Common Viral Infections*. Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 6th edition, 2006.
34. **Maldonado YA, Arvin AM, Ruskin J, and Yeager AS:** *Less Common Protozoan and Helminth Infections*. Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 6th edition, 2006.
35. **Maldonado YA, Baker CO, Miller MJ:** *Pneumocystis and Other Less Common Fungal Infections*. Remington JS, Klein JO (Eds.) Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 6th edition, 2006.
36. **Maldonado YA:** *Epidemiology of HIV infection in children and adolescents*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 3rd edition, 2009.
37. **Maldonado YA:** *Prevention of HIV infection*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 3rd edition, 2009.

38. **Maldonado YA:** *Rubella virus*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 3rd edition, 2009.
39. **Maldonado YA:** *Rubeola virus (Measles and Subacute Sclerosing Panencephalitis)*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 3rd edition, 2009.
40. **Maldonado YA**, Nizet V, Klein J, Remington J, Wilson C: *Current Concepts of Infections of the Fetus and Newborn Infant*. Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 7th edition, 2011.
41. Shetty AK, **Maldonado YA:** *Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome in the Infant*. . Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 7th edition, 2011.
42. **Maldonado YA:** *Less Common Viral Infections*. . Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 7th edition, 2011.
43. **Maldonado YA:** *Less Common Protozoan and Helminth Infections*. . Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 7th edition, 2011.
44. **Maldonado YA:** *Pneumocystis and Other Less Common Fungal Infections*. . Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 7th edition, 2011.
45. **Maldonado YA**, Nizet V, Klein J, Remington J, Wilson C: *Current Concepts of Infections of the Fetus and Newborn Infant*. Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 6th edition, 2014.
46. Shetty AK, **Maldonado YA:** *Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome in the Infant*. . Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 8th edition, 2014.
47. Mcmillan, JA, **Maldonado YA:** *Less Common Viral Infections*. . Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 8th edition, 2014.
48. **Maldonado YA:** *Malaria and Less Common Protozoan and Helminth Infections*. Remington JS, Klein JO, Wilson C, Nizet V, Maldonado Y (Eds), Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders Company, Philadelphia, 8th edition, 2014.
48. Mathew R, **Maldonado YA:** *Measles*. Klein MW, Blaney S, Giardino, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS. (Eds), Rudolph's Pediatrics, McGraw Hill Education, New York, 23th edition, 2016.

49. Contopolous D, **Maldonado YA**: *Toxoplasmosis*. Klein MW, Blaney S, Giardino, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS. (Eds), Rudolph's Pediatrics, McGraw Hill Education, New York, 23th edition, 2016.
50. Shetty AK, **Maldonado YA**: *Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Infant*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 4th edition, 2016.
51. Troy SB, **Maldonado YA**: *Polioviruses*. Long S.S., Pickering L.K., and Prober C.G. (Eds.) Principles and Practice of Pediatric Infectious Diseases, Churchill Livingstone, New York, 4th edition, 2016.
52. Contopoulos-Ioannidis D, **Maldonado YA**. *Toxoplasmosis*. Kline MW, Blaney SM, Giardino AP, Orange JS, Penny DJ, Schutze GE, Shekerdemian LS (eds). Rudolph's Pediatrics, McGraw- Hill Education, New York, 23rd edition, 2018.